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ABSTRACT 
Several types of cancer, including bladder cancer, overexpress multiple receptor 
tyrosine kinases (RTKs), such as the c-Kit receptor and platelet derived growth factor 
receptor (PDGFR). Inhibitors of RTKs (RTKIs) are therefore used as targeted treatment 
options for patients with cancers that overexpress RTKs. A challenge associated with 
targeted therapies is the activation of alternative pro-survival signaling pathways, such 
as the cyclooxygenase-2 (COX-2) pathway, resulting in drug resistance. Although COX-
2 is over-expressed and promotes tumorigenesis in bladder cancer, it can be used as a 
biomarker for bladder cancer detection and treatment strategies.  
Conventional optical imaging technologies can detect advanced stages of 
bladder cancer; however, they have several limitations to detect early stages. Novel 
optical imaging agent, fluorocoxib A, is a rhodamine-conjugated analog of 
indomethacin, which selectively targets COX-2 expressing tissues. Fluorocoxib A can 
be used for the detection and monitoring of COX-2-expressing tumors during treatment.  
We evaluated the effects of RTKIs and COX inhibitors, alone and in combination, 
on human and canine bladder cancer cell lines in vitro. Despite inhibiting cellular 
proliferation and increasing apoptosis, tested RTKIs increased COX-2 expression. Co-
treatment of RTKIs and COX inhibitors abrogated the RTKI-induced COX-2 expression, 
indicating co-treatment may be more effective than either treatment alone.  
To evaluate the ability of fluorocoxib A for the detection of bladder cancer in 
mice, we used the carcinogen (N-butyl-N-4-hydroxybutyl nitrosamine, BBN) -induced 
bladder cancer mouse model that resembles human bladder cancer. The specific 
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uptake of fluorocoxib A by the bladder tissues correlated with the progression of bladder 
carcinogenesis and increased COX-2 expression, in contrast to normal bladder 
urothelium where no fluorocoxib A uptake was detected.  
We also investigated the RTKI-induced upregulation of COX-2 by evaluating the 
effects of RTKIs in vivo. Treatment of K9TCC#5Lilly xenograft tumors with AB1010 and 
imatinib increased COX-2 levels in the tumors of treated mice compared to the control 
group. The specific uptake of fluorocoxib A correlated with the treatment-induced 
increased COX-2 expression.  
Our results suggest that fluorocoxib A is a valuable optical imaging agent that 
can be used for detecting and monitoring early responses to targeted therapies in 
patients diagnosed with COX-2-expressing bladder cancer. 
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CHAPTER I INTRODUCTION: A REVEW OF CURRENT TREATMENT 
STRATEGIES AND DETECTION METHODS FOR BLADDER CANCER 
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BLADDER CANCER 
 
Bladder cancer in the United States is the 6th most common type of cancer, with 
an estimated 81,000 newly diagnosed cases and 17,000 deaths per year (1, 2). Bladder 
cancer incidence is three times higher in men than in women, which increases with age, 
as patients are generally diagnosed after 65 years of age. According to the World 
Health Organization (WHO), because of increased life expectancies, the rates of 
bladder cancer diagnoses are expected to increase over time (3, 4).  
The most common type of bladder cancer is urothelial carcinoma, also known as 
transitional cell carcinoma (TCC). Urothelial carcinoma arises from the epithelial cells 
that line the inner part of the bladder, known as the urothelium, and accounts for 90% of 
all bladder cancer cases. There are several additional subtypes of bladder cancer, 
including squamous cell carcinoma, small-cell carcinoma, and adenocarcinoma. These 
rare forms of bladder cancer are more aggressive, associated with high rates of 
metastasis, and patients generally have a poor response to standard therapy regimens. 
The most common symptom of bladder cancer is the presence of blood in the urine 
(hematuria), which occurs in most patients (5). There is a correlation between 
macroscopic hematuria and the diagnosis of advanced stage bladder cancer. Currently, 
there are no active screening protocols for bladder cancer, so many patients who 
present with microscopic hematuria are not adequately evaluated and are diagnosed at 
a later disease state (6). 
There are five primary stages of bladder cancer, with stage IV being the most 
advanced disease state (7). Stage 0 is classified as a non-invasive papillary carcinoma 
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or a flat, carcinoma-in-situ (CIS). Stage I, the cancer has spread to the layer of 
connective tissue in the bladder but not to the muscle layer of the bladder wall (non-
muscle invasive bladder cancer, NMIBC). Stage II, the cancer has progressed to the 
muscle layer of the bladder wall (muscle-invasive bladder cancer, MIBC). Stage III, the 
cancer has spread through the fatty layer surrounding the bladder as well as 
surrounding pelvic organs (prostate, uterus, or vagina). Stage IV, the most advanced 
stage, is characterized by metastatic bladder cancer throughout the lymphatic system 
and other organs. Patients diagnosed with Stage IV bladder cancer have poor 
prognostic outcomes (8). Approximately 75% of newly diagnosed cases are classified 
as NMIBC, and 25% are MIBC, with or without metastatic disease (9-11).  
The development of bladder cancer is associated with several risk factors 
including cigarette smoking, environmental factors, diet, occupational exposures, 
chronic bladder infections, and familial history of bladder cancer. Cigarette smoking 
accounts for almost half of the diagnosed cases, with a long lag time between exposure 
to tobacco and time of diagnosis (12). Environmental factors (contaminated drinking 
water, air pollution, etc.), diet, and alcohol consumption are indirect risk factors, and, 
when in combination with multiple risk factors, the risk of bladder cancer development 
increases (11, 13, 14). Occupational exposures include industrial workplaces, such as 
chemical processing plants, factories processing paint, rubber, and petroleum products, 
and mining locations, and prove to be the highest occupational risk areas (11, 15). 
Exposure to these hazards over time significantly increases the risk of developing 
bladder cancer. Another factor that accounts for approximately 10% of bladder cancer 
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cases is urbanization and the spread of manufacturing companies to under developed 
countries (16). There is an increasing indication that certain individuals due to their 
genetic makeup and mutations in specific genes have an increased risk for developing 
bladder cancer. More specifically, mutations in genes that are responsible for the 
breakdown of carcinogens, for example N-acetyl transferases, which play a role in the 
activating or inactivating of amine carcinogens, and GSTM1-null genotypes, where 
GSTM1 plays a role in detoxifying environmental carcinogens (17, 18). A previously 
published study determined that women who smoke cigarettes and have the GSTM1-
null genotype have a greater increased risk of developing bladder cancer compared to 
non-smoking women with the GSTM1-null genotype (19).  
As there is no approved screening method for the early detection of bladder 
cancer, a current focus of research is to evaluate the genetic components of bladder 
cancer for biomarkers correlated with the tumorigenesis of bladder cancer. These 
biomarkers can be used as a screen, equivalent to testing for mutations in the BRCA1/2 
genes for breast and ovarian cancers, as well as potential drug targets for the treatment 
of bladder cancer. To date, several genes with known mutations have been found to aid 
in the development and progression of bladder cancer, including activating mutations in 
the oncogenes Hras and fibroblast growth factor receptor (FGFR3). Mutations in the 
tumor suppressor genes Tp53, Rb1, and Pten also lead to the development and 
progression of many types of cancer, including bladder cancer. (20-25). The 
development of a screen for patients with a high risk of developing bladder cancer 
would prove to be extremely beneficial for early detection but the relatively low 
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incidence and lack of bladder cancer specific biomarkers proves to be a challenge at 
this time. To overcome these challenges, preclinical and clinical research has shifted in 
the direction of enhancing the detection methods currently used, including improving the 
evaluation of hematuria, cytology practices, and novel optical imaging during 
cystoscopy procedures. 
TREATMENT FOR BLADDER CANCER 
 
Treatment for bladder cancer is dependent on whether the cancer is non-muscle 
invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) at time of 
initial diagnosis. Standard treatment for NMIBC is a transurethral resection of the 
bladder tumor (TURBT) for the visualization and resection of the tumor. TURBT 
procedures are followed by intravesical adjuvant therapy due to high risk of recurrence 
and progression after TURBT procedures. TURBT procedures serve as a diagnostic 
and a therapeutic tool because the procedure can potentially provide a curative 
outcome for low-risk patients, depending on the location and pathology of the tumor. 
Intravesical adjuvant therapies following a TURBT procedure include standard 
chemotherapy (mitomycin C or gemcitabine) or immunotherapy (Bacille Calmette-
Guérin), either alone or in combination (26-28). Adjuvant therapies significantly 
decrease the risk of recurrence rates after the initial diagnosis when compared to no 
adjuvant therapy after TURBT procedures. The tumors from patients diagnosed with 
NMIBC are further characterized to determine the appropriate treatment regimen after 
TUBRT procedures (29). Despite the benefits of TURBT procedures, there is a high-risk 
of recurrence (>50%) associated with these procedures because of incomplete tumor 
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resection due to several factors, including the size and location of the tumor (30). This 
drives the need for accurate tumor staging after the initial TURBT procedures and 
repeat procedures for patients with known incompletely resected tumors to increase 
recurrence-free survival. Nonetheless, combined TURBT procedures and adjuvant 
therapy is highly beneficial to patients diagnosed with early stage bladder cancer as 
compared to those diagnosed with late stage bladder cancer. 
MIBC cases are managed with more aggressive treatment regimens. Currently, 
the gold-standard treatment for MIBC is an open radical cystectomy (ORC) followed by 
adjuvant platinum-based chemotherapy (31, 32). Due to higher complications and 
invasiveness of the ORC procedure, less invasive methods have been explored 
including a laparoscopic radical cystectomy (33). The benefits of a less invasive 
procedure include reduced blood loss, equivalent outcomes to invasive procedures, 
decreased complications during the procedures, and improved quality of life after the 
procedure (34-36). Regardless of how the radical cystectomy procedure is performed, a 
urinary diversion procedure is required to restore normal urine flow (37). Bladder 
preservation surgery is also an option for qualified patients followed by adjuvant 
therapies to significantly improve quality of life after surgery (38). These patients are 
considered low risk and the surgery must prove to be curative to prevent a radical 
cystectomy procedure (i.e. complete tumor resection with negative margins) (39).  
Survival outcomes for patients diagnosed with MIBC depends on initial 
pathological tumor staging. Patients who undergo a radical cystectomy and have 
negative lymph nodes (no metastasis) have a significantly higher progression free 
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survival rate when compared to patients diagnosed with metastatic disease state (40). 
The standard chemotherapy protocol for these patients is platinum-based therapeutics 
in combination with other chemotherapeutic agents. These drug combinations include 
cisplatin, methotrexate, vinblastine, doxorubicin, and gemcitabine. Despite high rates of 
recurrence and low patient median survival times, this protocol is still considered to be 
the standard first-line treatment option for patients diagnosed with advanced stage 
bladder cancer. 
For patients who do not respond to the standard chemotherapy regimens or their 
disease state is too advanced, second-line options may be available (41). Current FDA-
approved second-line therapies for late stage bladder cancer include systemic 
immunotherapy, for example the programmed cell death ligand (PD-L1) monoclonal 
antibody, atezolizumab (42). Additional immunotherapies are being evaluated in 
preclinical and clinical studies for the treatment of metastatic bladder cancer. The role of 
adjuvant therapy either prior to or after a radical cystectomy procedure has greatly 
improved survival for patients diagnosed with NMIBC and MIBC. Resistance to standard 
chemotherapy regimens has increasingly become a challenge for patients diagnosed 
with bladder cancer.  
Bladder cancer is one of the most expensive malignancies to treat due to lack of 
improved therapies over the past few decades and high rates of recurrence and 
resistance. To combat resistance, improve the standard of the care for patients, and 
increase patient survival, novel targeted therapies are being explored as second-line 
treatment options, including systemic immunotherapies and receptor tyrosine kinase 
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inhibitors, alone and in combination with current therapeutic options. Recently, 
immunotherapy has played a pivotal role in the treatment of many types of cancer due 
to the development and success of monoclonal antibodies, cancer vaccines, and 
cytokine therapies. Based on the success of immunotherapy for treatment of both 
hematologic cancers and solid tumors, the notion of using immunotherapy for the 
treatment of late-stage bladder cancer has emerged.  
The most commonly studied target for immunotherapy is the PD-1/PD-L1 
interaction due to the pivotal role it plays in the immune response to tumor development 
and the tumor microenvironment (43). The PD-1 receptor is expressed on the surface of 
activated T cells, and PD-L1, which is overexpressed on cancer cells, binds to the 
receptor to suppress the innate immune response. Cancer cells, therefore evade the 
innate immune response and result in tumor progression. Targeting both the PD-1 
receptor and its ligand, PD-L1, to block the binding of PD-L1 to the receptor can 
enhance the innate immune response and result in tumor suppression. There are 
several clinical trials in the process of evaluating monoclonal antibodies for the 
treatment of late-stage bladder cancer. As mentioned above, the FDA recently 
approved atezolizumab, which demonstrated a high success rate for patients diagnosed 
with PD-L1 positive metastatic bladder cancer (44). This treatment had minimal side 
effects compared to standard chemotherapy. Additionally, there are two early stage 
clinical trials being performed to evaluate anti-PD-1 monoclonal antibodies, 
pembrolizumab and nivolumab. Both have demonstrated to be well-tolerated, effective 
at inhibiting tumor growth, and have minimal side effects but these drugs are still in the 
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process of being evaluated for their effectiveness in increasing the overall progression-
free survival. Preliminary data indicates the one-year survival time for patients 
diagnosed with metastatic bladder cancer and who receive pembrolizumab, is 53% (45). 
These agents, and others, are still under investigation but have delivered promising 
results as second-line therapeutic options for patients diagnosed with metastatic 
bladder cancer. 
In addition to the PD-1/PD-L1 immune checkpoint, another pathway of interest 
for immunotherapy is targeting the cytotoxic T-lymphocyte-antigen 4 (CTLA4). By 
targeting CTLA4, the expected outcome is to increase the immune response directed 
towards the tumor cells by restoring activation of T lymphocytes and, therefore, 
activating the innate immune response to kill cancer cells. In 2010, the FDA approved 
the CTLA4 monoclonal antibody, ipilimumab, as a second-line therapeutic for metastatic 
melanoma (46). Again, based on the results demonstrated by ipilimumab to significantly 
increase patient survival with metastatic melanoma, the principle was applied to 
metastatic bladder cancer. Ipilimumab administration prior to radical cystectomy 
procedures demonstrated an increased anti-tumor immune response and significantly 
improved patient outcomes (47). Ipilimumab, in combination with gemcitabine and 
cisplatin, is currently in phase II clinical trials as a first-line agent for metastatic bladder 
cancer. An early phase clinical trial is also under investigation for the combination of 
nivolumab and ipilimumab as a second-line therapeutic strategy for advanced stage 
bladder cancer (with or without metastases).  
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More recently due to predicted challenges of targeted immunotherapies, cancer 
vaccines have been under investigation for the treatment of advanced stage bladder 
cancer as second-line therapeutic agents. There are several early phase clinical trials 
being conducted to evaluate the safety and efficacy of bladder cancer vaccines to 
activate the immune system of the patients, specifically targeting bladder cancer 
specific tumor antigens (48). Cancer vaccines are being evaluated alone and in 
combination with standard therapies in patients who demonstrate a high risk for 
recurrence (49, 50). More research still needs to be conducted to determine the efficacy 
of cancer vaccines for treatment bladder cancer.  
In addition to immunotherapy, another area of focus for the treatment of 
advanced stage bladder cancer is receptor tyrosine kinase inhibitors (RTKIs) (51). 
Receptor tyrosine kinases (RTKs), such as the c-Kit receptor, epidermal growth factor 
receptors (EGFR), fibroblast growth factor receptors (FGFR), platelet derived growth 
factor receptors (PDGFR), and the vascular endothelial growth factor receptors 
(VEGFR), are prime therapeutic targets because they are overexpressed in a variety of 
cancers, including bladder cancer, due to mutations that affect RTK signaling (52-54). 
Once activated by their specific ligands, RTKs play a key role in tumorigenesis by 
activating downstream, pro-survival signaling pathways that promote cell proliferation, 
differentiation, migration, increased angiogenesis, and anti-apoptotic cellular responses 
(55-58). First discovered in the 1980s and extensively studied since, RTKIs are small-
molecule inhibitors that bind to the active tyrosine kinase domain of RTKs to inhibit 
phosphorylation and activation of downstream signaling pathways to inhibit tumor 
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progression (59-62). RTKIs have proven to be highly selective, have minimal side 
effects compared to standard cytotoxic chemotherapy, and have significant treatment 
responses for patients diagnosed with cancer, including breast cancer, leukemia, lung 
cancer, renal cell carcinoma (RCC), and gastrointestinal stromal tumors (GIST) (63-71). 
To date, there are more than 20 FDA-approved RTKIs for cancer treatment and many 
more in the pre-clinical and clinical trial stages. Based on the success of RTKIs for 
treating solid tumors, the efficacy of RTKIs for the treatment of advanced stage bladder 
cancer is currently under pre-clinical and clinical investigation (72). 
Of the many genomic alterations associated with bladder cancer, there are 
several highlighted for effective RTKIs therapy, and clinical trials are underway. The 
most common pathways currently being evaluated are the epidermal growth factor 
receptors (EGFR), fibroblast growth factor receptors (FGFR), and phosphoinositide-3-
kinase/protein kinase b (PI3K/Akt) signaling pathways (73). There are several other 
RTKs overexpressed in bladder cancer, but the above-mentioned pathways are the 
pathways currently being evaluated, and inhibitors of those targets show the most 
promise for potentially becoming FDA-approved second-line therapeutic options for 
patients.  
The FGFR family of receptors has been extensively evaluated as a potential 
therapeutic target for advanced stage bladder cancer because of its role in many 
physiological processes, including tumorigenesis, angiogenesis, and drug resistance 
(74, 75). FGFR is highly overexpressed in advanced stage bladder cancer compared to 
NMIBC and is associated with a more aggressive bladder cancer phenotype (52, 76-
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78). The overexpression of FGFR and its roles in tumor progression indicate that FGFR 
is a strong therapeutic target. Several clinical trials are being conducted to evaluate the 
efficacy of novel FGFR-specific RTKIs, including the small-molecule inhibitors JNJ-
42756493, BGJ398, and dovitinib as second-line therapeutic options for patients with 
advanced metastatic bladder cancer (72, 79, 80). Preliminary results from these studies 
indicate effective anti-tumor responses and increased progression-free survival times 
for patients who received the therapy. The RTKIs demonstrated high specificity for the 
tumors with minimal side effects. Additional studies need to be performed due to 
intrinsic drug resistance discovered in patients that harbor FGFR3 mutations (81, 82). 
Nonetheless, RTKIs specific to the FGFR seem to be a promising therapeutic option for 
patients who do not respond to standard chemotherapeutic options.  
The EGFR family of receptors is highly overexpressed in human cancers arising 
from epithelial cells, including lung and bladder cancer. This family of receptors plays a 
key role in regulating cell proliferation, angiogenesis, apoptosis, and metastasis (83). 
EGFR is commonly expressed in MIBC, and expression correlates with poor patient 
prognosis (84, 85). The overexpression of EGFR in bladder cancer cells makes this 
receptor a suitable therapeutic target for the treatment of bladder cancer. Several pre-
clinical and clinical studies are being conducted to evaluate the efficacy of RTKIs that 
specifically target EGFR. These studies are based on the results from a previously 
published pre-clinical study that evaluated the efficacy of the monoclonal antibody, 
cetuximab, alone and in combination with chemotherapy (86). Cetuximab is FDA-
approved for treating EGFR-expressing non-small-cell lung, head and neck, and 
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colorectal cancers. Results from this study indicated that by inhibiting EGFR, 
angiogenesis was decreased, and anti-tumor effects were enhanced when combined 
with chemotherapy. This study confirmed that EGFR is a strong target for novel bladder 
cancer therapies.  
There are two FDA-approved RTKIs, gefitinib and erlotinib, demonstrating strong 
anti-tumor effects in EGFR-expressing cancers, primarily lung cancer. Both gefitinib and 
erlotinib are EGFR-selective inhibitors. Pre-clinical studies show gefitinib, alone and in 
combination with chemotherapeutic agents, has strong anti-tumor effects by inhibiting 
EGFR phosphorylation and downstream pro-survival Akt signaling (87). A clinical study 
by the Southwest Oncology Group, determined that administration of gefitinib alone to 
patients, who previously had been treated with chemotherapy, did not see success with 
this therapy (88). Progression free survival was significantly decreased, and more than 
half of the patients experienced tumor progression. Further clinical investigation into the 
efficacy of gefitinib as a second-line therapy option determined that patients, who had 
not received prior chemotherapy and were treated simultaneously with gefitinib and 
standard chemotherapy simultaneously, had an increased progression-free survival 
time (89). The results of this study did not demonstrate that gefitinib significantly 
increased anti-tumor responses compared to chemotherapy alone. The studies 
evaluating gefitinib as a second-line therapy option for advanced stage bladder cancer 
are similar to the results obtained when gefitinib was evaluated as a therapeutic agent 
for the treatment of lung cancer (54, 88-91). Patients may initially respond to the 
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therapy, but overtime there is disease progression and eventually no response to the 
therapy. These results demonstrate one of the major challenges of targeted therapies.  
Erlotinib is an EGFR-selective RTKI that has been evaluated in many types of 
EGFR-expressing cancers. Erlotinib was evaluated in clinical studies as a second-line 
therapeutic option for patients diagnosed with advanced stage bladder cancer, but 
similar to the results obtained during the gefitinib studies, erlotinib does not prove to be 
an effective treatment option for bladder cancer patients (91, 92). In these studies, there 
was a poor patient response, despite high EGFR expression in the primary tumor cells. 
An investigation as to why the patients did not respond is currently being conducted. 
Poor response to EGFR-targeted therapy has been a challenge for the treatment of 
bladder cancer. The mechanisms of resistance are being investigated, but it may be 
related to the number of EGFR mutations that are found in bladder cancer (93). These 
results would be like those of lung cancer, and many patients do not respond to certain 
EGFR-targeted therapies due to specific mutations found in the tumor cells. These 
results drive the need for better characterization of the mechanisms of drug resistance 
and further enhance the need for early detection of therapy responses for improved 
treatment of bladder cancer.  
Despite being located downstream of RTKs, the PI3K/Akt signaling pathway 
plays a crucial role in promoting cell proliferation, angiogenesis, anti-apoptosis, and 
tumor progression. This pathway is commonly overexpressed in many types of cancer, 
including advanced stage bladder cancer. (52). To inhibit this pathway, the current 
protocol is to administer mammalian target of rapamycin (mTOR) inhibitors to patients 
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with high PI3K/Akt mutations. mTOR is downstream of PI3K/Akt, and by inhibiting 
mTOR, activation of downstream pro-survival signaling pathways is inhibited, resulting 
in cell death. There are several mTOR inhibitors being evaluated alone and in 
combination with cytotoxic chemotherapy, including rapamycin and its analogs - 
everolimus, temsirolimus, and sirolimus, as second-line therapy options for patients with 
advanced stage bladder cancer. Preliminary results from these studies indicate that 
mTOR inhibitors, when in combination with another therapeutic agent (chemotherapy or 
targeted therapy), increase in patient progression-free survival (94-97). Further studies 
need to be conducted to evaluate mTOR inhibitors alone as a second-line therapy 
option due to mixed patient results (95, 96, 98). Results of the above-mentioned studies 
indicate that mTOR inhibitors alone may not elicit an anti-tumor response and increase 
patient survival superior to chemotherapy alone. There are also several early stage 
clinical trials being conducted, evaluating the efficacy of PI3K inhibitors for metastatic 
bladder cancer, including the GSK458 and buparlisib inhibitors (99).  
Briefly, VEGFR is also highly overexpressed in bladder cancer and is a prime 
target for monoclonal antibody therapies (i.e. bevacuzimab). The RTKI sunitinib has 
been evaluated in patients who do not respond to standard chemotherapy. In pre-
clinical studies, sunitinib has enhanced the anti-tumor effects of the chemotherapy 
combination, cisplatin and gemcitabine (100). When administered to patients, sunitinib, 
like the FGFR inhibitor dovitinib, mixed results were observed (101). When used in 
combination with standard chemotherapy, the side effects were not tolerable, and the 
combination was too toxic for patients to continue with this regimen. At best, stable 
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disease was achieved, but progression-free survival was not superior to chemotherapy 
alone (102). Pre-clinical studies are still being conducted to evaluate the efficacy of 
sunitinib, but clinical trials are not being continued at this time.  
The current and novel therapeutic strategies described in the section above 
provides insight into why there has been little change in the standard of care protocols 
for patients diagnosed with bladder cancer. Patients diagnosed with NMIBC have a 
significantly greater 5-year survival rate than patients diagnosed with MIBC, because, if 
caught early, surgery can be a curative procedure. These patients also respond better 
to standard intravesical chemotherapy and immunotherapy regimens than those who 
are diagnosed at a later disease state. Many of the novel therapeutic strategies are 
focused on improving patient survival outcomes for those diagnosed with advanced 
stage bladder cancer. The pre-clinical studies in this dissertation evaluate RTKIs for the 
treatment of bladder cancer in vitro and in vivo. These studies also address some of the 
challenges associated with targeted therapies, including resistance, and evaluate 
therapeutic strategies to overcome these challenges. 
DETECTION OF BLADDER CANCER 
 
The detection of cancer through imaging has been one of the most widely 
studied areas in cancer research. It is well known that early detection of cancer results 
in significantly improved patient prognostic outcomes and curative treatment options (4). 
There has been a recent shift in clinical diagnostic imaging to better visualize the tumors 
and sites of metastasis. Traditional FDA-approved imaging modalities for cancer 
detection include computed x-ray tomography (CT), magnetic resonance imaging (MRI), 
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ultrasound (US), and more recently positron emission tomography (PET) (103-106). 
These imaging modalities have changed the way cancer is detected and have 
significantly improved patient outcomes. They are still widely used throughout clinical 
settings and demonstrate continued success. Researchers and clinicians combined 
have demanded more information to be extracted from the obtained images and 
overcome limitations of traditional modalities which drives the need for improved 
molecular imaging modalities. There are several goals of molecular imaging research 
that are being investigated including the development of molecular biomarkers that can 
aid in the early detection of cancers, the ability to evaluate the early responses to 
therapy, and the development of imaging tools to evaluate tissues microscopically in 
real-time, not just macroscopically (106-108). The need for early detection of bladder 
cancer falls in line with these goals. Current imaging modalities have several limitations 
for the detection of the early stages of bladder cancer and therefore drives the need for 
improved optical imaging modalities. Those limitations and promising novel optical 
imaging modalities are further discussed in this section as well as the following in vitro 
and in vivo studies of this dissertation.  
The initial process for evaluating patients presenting with bladder cancer 
symptoms is by performing an optical imaging procedure known as a cystoscopy (109). 
This procedure allows for the visualization of the inner surface layer of the bladder to 
determine if any abnormal lesions are present. White light cystoscopy (WLC) is the 
current standard of care for detecting papillary lesions or large growths. WLC has been 
used for several decades to detect and remove bladder tumors, but there are several 
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limitations associated with WLC, including the inability to detect early-stage bladder 
cancer (carcinoma in situ and low-grade tumors), as well as the inability to detect tumor 
margins during resection procedures, leading to incomplete resection of the tumor 
(110). If abnormal lesions are found during the procedure, histological evaluation is 
required to confirm the diagnosis of bladder cancer and determine the stage of the 
tumor. A urine cytology can also be performed along with the cystoscopy procedure to 
detect any missed cancer cells as the early stages of bladder cancer (flat lesions and 
carcinoma in situ) are often missed. As previously mentioned, there are currently no 
bladder cancer biomarkers present in urine that have demonstrated the necessary 
success rates for approval in clinical diagnostic use (111-113).  
WLC is the gold standard for initial bladder cancer detection, but there are 
several other imaging modalities that are currently used, including CT, MRI, and PET 
imaging (114). These imaging modalities are most commonly used to aid in the 
detection of advanced stage bladder cancer as there are several limitations for these 
modalities to be used for early stage bladder cancer detection. CT or MRI scans are 
necessary for patients diagnosed with advanced stage bladder cancer to determine the 
infiltration of the tumor through the layers of the bladder and if there are any sites of 
metastasis. These scans, along with histopathology, will aid in determining the stage of 
the bladder tumors. CT scans are relatively inexpensive, easy to obtain, and can detect 
advanced stage tumors. There are several limitations associated with CT, including 
exposure of patients to ionizing radiation, lack of ability to determine lymph node 
involvement, large range of specificity, low resolution to differentiate between the 
19 
 
different layers of the bladder, and cannot detect flat or CIS bladder tumors (115-119). 
MRI scans can be used for the detecting and staging advanced bladder cancer. This 
method demonstrates high sensitivity and specificity, while not exposing patients to 
ionizing radiation. MRI can also be used to improve the accuracy of tumor staging after 
a cystoscopy or TURBT procedure and proves to be superior to CT scans in 
differentiating between the early stages of NMIBC (120, 121). Despite these 
improvements in detecting bladder cancer, there are several limitations of MRI as an 
imaging modality. These limitations include high cost for patients, reliance on normal 
functioning kidneys due to the contrast agent used (gadolinium), and limited ability to 
determine the extent of the primary tumor invasion through the layers of the bladder 
(122).  
An emerging imaging modality commonly used for metastasis detection is PET 
scans. This imaging technique relies on the administration of a contrast agent, 
fluorodeoxyglucose (FDG), which takes advantage of one of the hallmarks of cancer, 
increased glycolysis activity within the cancer cells or the Warburg effect. Unfortunately, 
FDG is excreted through the urinary system and therefore is not a good contrast agent 
for the detection of tumors in the bladder. Therefore, FDG-PET scans can be used for 
the detection of metastatic lesions throughout the body and a review of previous clinical 
studies demonstrate the success of detecting metastatic bladder cancer in patients 
using FDG-PET scans (123). FDG-PET scans also prove to be superior at detecting 
lymph node involvement and metastatic lesions before and after therapy when 
compared to MRI or CT scans (124-126).  The improved detection of advanced stage 
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bladder cancer has significantly improved patient prognostic outcomes by extending the 
duration of progression-free survival times.  A significant limitation of FDG-PET scans is 
the inability to detect primary bladder tumors.     
Conventional optical imaging technologies can detect advanced stages of 
bladder cancer; however, they are limited in detecting bladder cancer at the early 
stages. Newer imaging technologies have been developed to prevent disease 
recurrence and progression (127, 128). There are four primary novel optical imaging 
technologies that have recently been investigated for clinical diagnostic use: 
fluorescence cystoscopy/photodynamic diagnosis (PDD), narrow band imaging (NBI), 
confocal laser endomicroscopy (CLE), and optical coherence tomography (OCT) (129, 
130). Fluorescence cystoscopy/PDD and NBI are used as diagnostic tools to better 
visualize the tumors and optimize detection of early stage bladder cancer lesions. On 
the contrary, CLE and OCT are used to characterize the detected lesions to improve 
accuracy in determining the grade and stage of the lesions. 
Fluorescent cystoscopy requires the administration of a contrast agent, which 
selectively binds to the cancer cells. Photodynamic diagnosis/blue-light cystoscopy 
(BLC) is an FDA-approved procedure, which requires the administration of 5-
aminolevulinic acid (5-ALA) dye directly into the bladder (131, 132). The dye is 
absorbed by the cancerous tissue and emits a red color under blue light to better 
visualize the tumor during cystoscopy. This method is currently being used during 
TURBT procedures and for detecting early-stage bladder cancer. Previous studies 
suggest BLC can detect more bladder tumors than WLC, both early and late stage 
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tumors (132-136). There are several advantages to fluorescent cystoscopy, including 
better visualization and differentiation of the cancer tissue from normal urothelium, 
detection of early stage bladder cancer, and tumor margins can be easily visualized 
during resection procedures (137). This technique improves diagnosis and decreases 
recurrence rates after TURBT procedures. There are some inconsistencies with high-
false positive rates and high equipment costs. This drives the need for improved optical 
imaging modalities for detecting bladder cancer.  
Narrow band imaging (NBI) is a novel endoscopy imaging modality that has been 
FDA-approved for clinical diagnostic use in the United States. This method of imaging 
does not require the administration of a contrast agent prior to imaging and relies on 
filters specialized for the blue and green light spectrum wavelengths (415 nm and 540 
nm, respectively) that are absorbed by hemoglobin. Based on this principle, during 
cystoscopy procedures enough contrast is provided to visualize increased blood vessel 
formation indicative of bladder cancer development. This non-invasive method has 
significantly improved NMIBC detection compared to WLC alone (138). There have 
been a few clinical studies evaluating the effectiveness of NBI for detecting bladder 
cancer, but the results of those studies confirm NBI is more effective than WLC alone 
for detecting NMIBC (139-141). Consistent with fluorescent cystoscopy, it can be 
inferred that better detection of initial tumor sites can result in more effective treatment 
and decreased recurrence rates of bladder cancer. Consistent with all endoscopic 
techniques, NBI is not capable of determining tumor grade and stage during the 
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procedure. Histopathology analysis is required for further evaluation and treatment 
options. 
 To have the ability detect and properly stage bladder tumors during the 
diagnostic process, microscopic imaging modalities, such as CLE and OCT, are 
required. Both modalities are in the early stages of investigation and have not been 
approved by the FDA for clinical diagnostic use yet. These modalities allow for real-time 
histopathology information to be collected and evaluated during the diagnostic 
cystoscopy procedures. CLE has previously been evaluated and demonstrated a high 
success rate for the detection of gastrointestinal tumors. During cystoscopy procedures 
when CLE is performed, the administration of a fluorescent contrast agent is required. 
The administration of a contrast agent allows for microscopic visualization of the tissue 
being examined. Due to high resolution and depth of imaging penetration, CLE allows 
for morphology identification of individual cells in real-time, which can be used to 
determine the grade (high or low) of the bladder tumors during the actual diagnostic 
procedure (142). There are several limitations of CLE, including CLE does not visualize 
flat or CIS lesions superior to WLC, and due to limited field of view during the 
procedure, this modality is time consuming and does not offer deep tissue penetration. 
Further studies are being conducted to merge different fields of view for analysis at one 
time.  
 Another optical imaging modality under investigation for the detection of bladder 
cancer is OCT, which, like CLE, allows for real-time microscopic imaging of the bladder 
during cystoscopy procedures. This method is comparable to ultrasound and relies on 
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the signal produced by light waves in the near-infrared spectrum to form an image of the 
bladder tissue. Like CLE, OCT demonstrates high resolution and tissue penetration for 
the detection of bladder cancer. OCT can differentiate between normal urothelium and 
cancerous tissue, but unlike CLE, OCT cannot determine the grade of tumors detected.  
OCT can determine how far the tumor has infiltrated into the bladder, which is known as 
the stage of the tumor. It is important to distinguish between NMIBC and MIBC because 
the course of treatment is dependent on the diagnosis of NMIBC or MIBC. Recent 
studies evaluating OCT for the detection of bladder cancer have demonstrated high 
sensitivity and specificity, indicating success of this modality (143, 144). OCT also have 
several limitations, including the difficulty to image the whole bladder. A recent study 
demonstrated that OCT, in combination with PDD, resulted in higher sensitivity and 
specificity than OCT alone (145). These results indicate that currently fluorescent 
cystoscopy and NBI are more superior to WLC alone. Further evaluation needs to be 
conducted to determine the efficacy of CLE and OCT as clinical diagnostic tools for the 
detection of bladder cancer, either alone or in combination with current detection 
modalities.  
As described above, the limitations of conventional optical imaging modalities 
have driven the need for the development of novel imaging modalities for the detection 
of early and late stage bladder cancer. An area of advancement in imaging is the 
evaluation of cancer-specific biomarkers for the detection of early stage cancer and 
determining complete tumor location for improved resection procedures. A biomarker of 
interest for the detection and treatment of bladder cancer is cyclooxygenase-2 (COX-2). 
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COX-2 converts arachidonic acid to prostaglandins and is highly inducible during 
periods of inflammation and cancer, including bladder cancer. COX-2 is not expressed 
in normal tissues, making it a suitable biomarker for COX-2-selective imaging and 
therapeutic agents. It is also one of the key proteins responsible for increased 
angiogenesis and tumorigenesis (146-149). Previous studies have demonstrated that 
increased prostaglandins production positively correlates with COX-2 expression levels 
and the progression of cancer (150-153). High COX-2 expression in bladder cancer is 
also indicative of poor patient prognostic outcomes (154).  To inhibit COX-2 expression, 
non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for the prevention 
and treatment of cancer (155-163). A side effect of long-term NSAIDs use is 
gastrointestinal toxicity (164). To reduce toxicity, COX-2 selective inhibitors (COXIBs), 
such as celecoxib and rofecoxib, have been developed (165, 166). These selective 
inhibitors have demonstrated success in effectively reducing the side effects in patients, 
while still effectively inhibiting COX-2 (160, 167-169). Due to increased heart attacks 
and strokes in patients with prolonged COX-2 selective inhibitors use, celecoxib 
remains the only COX-2 selective inhibitor on the market (170). These side effects 
further drive the need for improved novel therapies for patients with chronic 
inflammation and cancer.  
The overexpression of COX-2 in bladder cancer tissues can therefore be used as 
a biomarker for detecting bladder cancer. Fluorescently-labeled COX-2 inhibitors are 
suitable candidates for targeted optical imaging due to their highly selective uptake by 
cancer cells. Fluorocoxib A is a rhodamine-conjugated analog of indomethacin that 
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selectively targets COX-2 in solid tumors (171). This imaging agent selectively targets 
the COX-2 enzyme, and when bound to the active site of COX-2, fluorescence is 
emitted. Fluorocoxib A has been previously validated for the detection of LPS-induced 
inflammation in a rat model (171) and in COX-2-expressing cancers in vitro and in vivo 
(172-174).  A previous study conducted by Cekanova et al., demonstrated that 
fluorocoxib A can specifically detect COX-2-expressing bladder cancer in dogs, and 
there is no uptake by the normal bladder urothelium (172). Fluorocoxib A has 
demonstrated high specificity and sensitivity for the detection of COX-2 expressing 
inflammation and cancer with little to no side effects in vivo. These pre-clinical results 
indicate that fluorocoxib A can be used for the detection and monitoring the responses 
to therapy in COX-2-expressing bladder cancer. The following studies in this 
dissertation evaluate fluorocoxib A as a novel optical imaging agent for the detection of 
early and late stage bladder cancer, as well as monitoring the responses to targeted 
therapies in vivo using two established bladder cancer mouse models.  
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RECEPTOR TYROSINE KINASE THERAPIES IN BLADDER CANCER 
CELLS IN VITRO 
  
48 
 
Research article described in this chapter is a slightly modified version of an article that 
was published in the Dove Press journal, Drug Design, Development, and Therapy, by 
Jennifer Bourn and Maria Cekanova in June 2018.  
 
Republished with permission of Dove Medical Press Ltd., from Cyclooxygenase 
inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro. 
Jennifer Bourn and Maria Cekanova. Drug Design, Development, and Therapy. 
2018:12. DOI: 10.2147/DDDT.S158518; permission conveyed through Copyright 
Clearance Center, Inc. Copyright © 2018 Bourn and Cekanova.  
 
In this paper, “our” or “we” refers to my co-author and me. My contribution to this 
manuscript includes: 1) Compiling and interpretation of literature, 2) Providing 
comprehensive structure to the paper, 3) Acquisition and analysis of data, and 4) 
Writing and editing of the manuscript. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
ORIGINAL RESEARCH 
Running title: COX inhibition potentiates RTKI therapies. 
Bourn and Cekanova. 
 
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in 
bladder cancer cells in vitro. 
Jennifer Bourn1,2 and Maria Cekanova1,2, *  
1Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The 
University of Tennessee, Knoxville, Tennessee, 37996, USA 
2UT-ORNL Graduate School of Genome Science and Technology, The University of 
Tennessee, Knoxville, Tennessee, 37996, USA 
 
*Correspondence: 
Maria Cekanova, RNDr, PhD; Research Associate Professor, Department of Small 
Animal Clinical Sciences, The University of Tennessee, College of Veterinary Medicine, 
2407 River Drive A122, Knoxville, TN 37996-4550; USA, Tel: 865-389-5222; Fax: 865-
974-5554; E-mail: mcekanov@utk.edu 
 
 
 
50 
 
ABSTRACT 
 
Purpose: Receptor tyrosine kinase inhibitors (RTKIs) are used as targeted therapies for 
patients diagnosed with cancer with highly expressed RTKs, including the platelet-
derived growth factor receptor (PDGFR) and c-Kit receptor. Resistance to targeted 
therapies is partially due to the activation of alternative pro-survival signaling pathways, 
including cyclooxygenase-2 (COX-2). In this study, we validated the effects of two 
RTKIs, axitinib and AB1010, in combination with COX inhibitors on the Akt and COX-2 
signaling pathways in bladder cancer cells.  
Methods: The expression of several RTKs and their downstream signaling targets were 
analyzed by western blot analysis in three human and two canine bladder transitional 
cell carcinoma (TCC) cell lines. The effects of RTKIs and COX inhibitors in bladder TCC 
cells were assessed by for cell viability, Caspase 3/7 and Annexin V assay for 
apoptosis, western blot analysis for detection of COX-2 and Akt signaling pathways, and 
by ELISA assay for detection of PGE2 levels.  
Results: All tested TCC cells expressed the c-Kit and PDGFRα receptors, except 
human 5637 cells that had low RTKs expression. In addition, all tested cells expressed 
COX-1, COX-2, Akt, ERK1/2, and NF-κB proteins, except human UM-UC-3 cells, where 
no COX-2 expression was detected by WB analysis. Both RTKIs inhibited cell viability 
and increased apoptosis in a dose-dependent manner in tested bladder TCC cells, 
which positively correlated with their expression levels of the PDGFRα and c-Kit 
receptors. RTKIs increased the expression of COX-2 in h-5637 and K9TCC#1Lillie cells. 
Co-treatment with the non-selective COX inhibitor, indomethacin, abrogated the 
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AB1010-induced COX-2 expression leading to an additive effect in inhibition of cell 
viability and PGE2 production in tested TCC cells.   
Conclusions: Co-treatment of RTKIs with indomethacin inhibited cell viability and 
inhibited AB1010-induced COX-2 expression resulting in decreased PGE2 production in 
tested TCC cells. Thus, COX inhibition may further potentiate RTKIs therapies in 
bladder cancer. 
 
Key words: transitional cell carcinoma, axitinib, masitinib, cyclooxygenase-2, 
prostaglandin E2, indomethacin  
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INTRODUCTION 
 
Bladder cancer is the 6th most common cancer in the United States and accounts 
for 4.6% of all new cancer cases (1). An estimated 81,000 new patients will be 
diagnosed with bladder cancer, and an estimated 17,000 deaths will occur as a result of 
the disease each year.1 Bladder cancer incidence is three times higher in men than in 
women. The most commonly diagnosed type of bladder cancer is urothelial carcinoma, 
also known as transitional cell carcinoma (TCC), which accounts for over 90% of all 
bladder cancer cases in the United States (1).   
The early detection and development of novel targeted therapies with higher 
efficacy and fewer adverse events as compared to commonly used chemotherapy 
treatments are currently a primary focus in research for bladder cancer treatment (2) 
Receptor tyrosine kinase inhibitors (RTKIs) are used for patients diagnosed with bladder 
cancer that have high expression of RTKs, including the platelet-derived growth factor 
receptor (PDGFR), c-Kit receptor, epidermal growth factor receptor (EGFR) (3,4), or 
vascular endothelial growth factor receptor (VEGFR) (5). Currently used RTKIs for the 
treatment of bladder cancer are monoclonal antibodies, including cetuximab (4,6) and 
bevacizumab (7,8), and small molecules, including gefitinib (9), sunitinib (10), and 
axitinib (11). Axitinib (also known as AG013736 or Inlyta® Pfizer, USA) is a potent RTKI 
(VEGFR IC50 = 0.1-0.3 nM, c-Kit IC50 = 1.7 nM, and PDGFR IC50 = 1.6nM) therapy 
option for patients diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12). 
Axitinib significantly increases progression-free survival rates in patients with RCC when 
compared to those treated with sorafenib (13). AB1010 (known also as Masitinib®, 
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Masivet®, Kinavet® AB Science, France) is a novel RTKI that targets the c-Kit (IC50 = 
200 nM) and PDGFRα/β (IC50 = 540-800 nM) receptors (14). Previous studies 
demonstrate the effectiveness of AB1010 as a viable treatment option for canine mast 
cell tumors by reducing cell viability and degranulation of mast cells without cytotoxic 
effects (15,16). AB1010 can act as a chemo-sensitizer by increasing the sensitivity of 
canine bladder, breast, and osteosarcoma cancer cells to chemotherapy agents in vitro 
(17-19). Similar favorable results have also been demonstrated with AB1010 in 
combination with gemcitabine in human pancreatic cancer cells in vitro (20). Preliminary 
results from a pre-clinical trial with AB1010 for patients diagnosed with imatinib-resistant 
gastrointestinal stromal tumors (GIST) indicate that AB1010 is well-tolerated and 
increases overall patient survival (21).  
Cyclooxygenase-2 (COX-2) is highly expressed in bladder cancer and is one of 
the key proteins responsible for angiogenesis (22,23) and tumorigenesis 
(24,25). Increased prostaglandins production positively correlates with COX-2 
expression levels and progression of cancer (26-29). Non-steroidal anti-inflammatory 
drugs (NSAIDs), inhibitors for COX enzymes, are commonly used for the prevention 
and treatment of cancers (30-34). One of the common side effects of long-term NSAIDs 
usage is gastrointestinal toxicity (35,36). The development of COX-2 selective inhibitors 
(COXIBs), such as celecoxib (37,38), effectively reduces the side effects in patients (39-
43). Several studies have shown that RTKIs increase COX-2 expression, which can 
possibly lead to therapy resistance (39,44,45). The cross-talk between the RTK and the 
COX-2 signaling pathways plays a key role in tumorigenesis (46,47).  
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 In this study, we evaluated the efficacy of axitinib and AB1010 (RTKIs) in a co-
treatment with indomethacin (NSAID) in bladder TCC cells in vitro. We have validated 
the anti-proliferative and pro-apoptotic effects of axitinib and AB1010 alone and in 
combination with indomethacin through regulation of COX-2 activity in bladder TCC 
cells in vitro. 
 
MATERIALS AND METHODS 
 
Reagents and antibodies 
AB1010 (Masitinib®) was obtained from AB Science (Paris, France); axitinib was 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and indomethacin was obtained 
from a laboratory of Dr. Lawrence Marnett (Vanderbilt University, Nashville, TN). The 
antibodies for COX-2 (C-20), COX-1 (H-62), PDGFRα (C-20), p-PDGFRα (Tyr720), p-
ERK1/2 (E-4), p-Akt (Ser473), c-Kit (961-976), p-c-Kit (Tyr721), Akt1/2/3 (H136), 
ERK1/2 (K-23), caspase-3 (H-277), actin, and rabbit anti-goat secondary antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); antibody for p65 
(NF-κB) was purchased from BD Biosciences (San Jose, California); PARP (recognize 
total and cleaved PARP), cleaved caspase-3 (D175), secondary anti-rabbit and anti-
mouse antibodies were obtained from Cell Signaling (Boston, MA). All other chemicals 
and reagents were purchased from Thermo Fisher Scientific (Pittsburgh, PA), unless 
otherwise specified. 
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Cell lines 
Human bladder transitional cell carcinoma (TCC) cell lines h-UM-UC-3, h-T24, 
and h-5637 were purchased from American Type Culture Collection (ATCC, Manassas, 
VA). Cell lines were authenticated via short tandem repeat (STR) DNA profiling by 
Genetica DNA laboratories (Burlington, NC). Human T24 cells were grown in McCoy’s 
media (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA), human UM-UC-3 cells were 
grown in minimum essential media (GE Healthcare Bio-Sciences), and human 5637 
cells were grown in RPMI-1640 media (GE Healthcare Bio-Sciences) supplemented 
with 10% fetal bovine serum, 100 I.U. penicillin, and 100 μg/mL streptomycin. Canine 
bladder transitional cell carcinoma (K9TCC) cell lines, K9TCC#1Lillie and K9TCC#5Lilly 
were established and characterized in the laboratory of Dr. Cekanova as described 
previously in detail (40,48,49). The K9TCC#1Lillie and K9TCC#5Lilly were grown in 
complete RPMI-1640 media supplemented with 10% fetal bovine serum, 100 I.U. 
penicillin, and 100 μg/mL streptomycin. Cells were grown at 37°C and 5% CO2. 
 
Proliferation (MTS) assay 
Cells were plated in 96-well plates at concentration of 5 x 103 cells/well in 
complete media. After 24 h incubation, cells were treated with AB1010, axitinib, 
indomethacin, or celecoxib (data not shown) in dose-dependent manners alone or in 
combinations (as specifically shown in Results section) in complete media for an 
additional 48 h. Vehicle, DMSO, was used as a control. After treatment, cell viability was 
measured using MTS CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
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(Promega, Madison, WI) according to manufacturer’s protocol. Briefly, 20 μl of the MTS 
reagent was added to each well and incubated with cells at 37°C for 1 h. Absorbance 
was measured at 490 nM using an FLx800 plate reader (Bio-Tek instruments, Winooski, 
VT). The data were shown as mean ± S.E. of four replicates of three independent 
experiments and normalized to the DMSO controls. 
 
Annexin V-FITC detection of apoptosis by flow cytometry 
Human 5637 and canine K9TCC#1Lillie bladder TCC cells were plated in 6-cm 
tissue culture dishes at density of 1 × 106 cells/dish in complete media. After 24 h of cell 
seeding, the cells were treated with DMSO (vehicle), axitinib (5 µM), and AB1010 (5 
µM). After 24 h treatment, both the media and attached cells were collected for analysis. 
Cells were stained with Annexin V-FITC and propidium iodide (PI) according to the 
TACS® Annexin V kit protocol (Trevigen, Inc., Gaithersburg, MD). The apoptotic cells 
were identified using a MACSQuant10 Flow Analyzer (Miltenyi Biotec Inc., Auburn, CA).  
 
Caspase 3/7 assay 
Cells were plated in 10-cm tissue culture dishes at density of 2 x 106 cells/dish in 
complete media. Twenty-four hours after seeding, cells were treated with AB1010 or 
axitinib (1, 5, 10 µM) for an additional 24 h in media without serum. After treatment, cell 
lysates were harvested using RIPA buffer supplemented with protease and 
phosphatase inhibitors cocktail (1 mM PMSF; 1 μg/ml aprotinin; 1 μg/ml leupeptin; 
0.1 mM Na3VO4; 10 mM NaF). Protein concentrations were measured using Pierce® 
57 
 
BCA protein assay (Thermo Scientific, Rockford, IL). Twenty-five micrograms of 
proteins were used for detection of caspases 3/7 activities following the Caspase Glo® 
3/7 Substrate manufacturer’s protocol (Promega, Madison, WI). After 1 h incubation 
with reagents, the luminescence signals were measured using an FLx800 plate reader 
(Bio-Tek instruments, Winooski, VT). The data were shown as mean ± S.E. of two 
replicates of three independent experiments and normalized to the DMSO-treated 
controls. 
 
Western blotting  
Human and canine bladder TCC cells were plated in 10-cm tissue culture dishes 
at density of 2 x 106 cells/dish in complete media and allowed to attach for 24 h. The 
cells were then treated with or without serum, with drugs in a dose-dependent manner 
alone, or in combinations for 24 h as mentioned in figure legends. After treatments, the 
cells were lysed in ice-cold RIPA buffer supplemented with protease and phosphatase 
inhibitors cocktail and kept at -80°C until WB analyses were performed. Protein 
concentrations were measured using the BCA protein assay. Equal amount of proteins 
was loaded onto SDS-PAGE gels and transferred to a nitrocellulose membrane. After 
blocking, the membranes were incubated with primary antibodies overnight at 4˚C. Next 
day, membranes were incubated with horseradish peroxidase-conjugated secondary 
antibodies (1: 3,000 dilution) for 45 min at room temperature, and immuno-reactive 
bands were visualized using the chemiluminescence system using ECL reagents. The 
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images were captured using the BioSpectrum® 815 imaging system (UVP, Upland, 
CA). 
 
PGE2 ELISA assay 
Human 5637 and K9TCC#1Lillie bladder TCC cells were plated in 10-cm tissue 
culture dishes at density of 2 x 106 cells/dish in complete media for 24 h followed by the 
treatment with 5 µM AB1010 and 50 µM indomethacin alone or in combination for an 
additional 24 h in serum free media. After the treatment, the media were collected, and 
dead cells and debris were removed by spinning down the media in pre-chilled tubes. 
Collected media were stored at -80°C until the PGE2 analysis was performed. One 
hundred microliters of media were used for PGE2 analysis following the manufacturer’s 
protocol for the PGE2 EIA kit (Enzo Life Sciences, Plymouth Meeting, PA). PGE2 
concentration was measured at an optical density of 405 nm with correction between 
570 and 590 nm using an FLx800 plate reader (Bio-Tek instruments, Winooski, VT). A 
standard curve was generated by using the Gen5TM 4 parameter logistic curve fitting 
software (Bio-Tek instruments) based on the PGE2 standards and the treated sample 
concentrations were calculated accordingly. The data is shown as mean ± S.E. of six 
replicates of three independent experiment and normalized to the control groups 
(DMSO, vehicle treated groups). 
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Statistical analysis 
Statistical analyses were conducted using the Student's t-test to establish 
significant differences among treatment groups. Results were considered statistically 
significant at *p < 0.05, **p < 0.01, and ***p < 0.001 to control, DMSO group. Student's 
t-tests were performed to compare co-treatment AB + Indo to AB treatment groups and 
results were considered statistically significant at #p < 0.05, ##p < 0.01, and ###p < 0.001. 
Student's t-tests were performed to compare co-treatment AB + Indo to Indo treatment 
groups and results were considered statistically significant at †p < 0.05, ††p < 0.01, and 
†††p < 0.001. 
 
RESULTS 
 
The expression profile of RTK- and COX-signaling pathway proteins in tested 
bladder TCC cells 
 The expression profile of RTKs, COXs, and their downstream targeted proteins 
were tested in human (h-UM-UC-3, h-T24, and h-5637) and canine (K9TCC#1Lillie and 
K9TCC#5Lilly) bladder TCC cells by WB analysis as shown in Fig. 2.1. While h-UM-UC-
3 cells expressed relatively high levels of c-Kit and PDGFRα receptors, h-T24 cells had 
only low and h-5637 had no detectable protein levels of PDGFRα and c-Kit receptors. 
K9TCC cell lines, K9TCC#5Lilly and K9TCC#1Lillie had relatively higher expression of 
PDGFRα and c-Kit receptors as compared to levels detected in h-TCC cell lines. All 
tested bladder TCC cells had high levels of phosphorylated ERK1/2 (p-ERK1/2) protein. 
In addition, h-5637 cells had the lowest levels of p-ERK1/2 expression, but the highest 
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expression of phosphorylated Akt (p-Akt) protein as compared to the other human 
bladder TCC cells. Both tested canine bladder TCC cell lines had higher p-ERK1/2 
expression, but no detectable p-Akt expression, when compared to h-TCC cell lines. 
Human UM-UC-3 and T24 cells had very low detectable COX-2 expression, whereas h-
5673, K9TCC#1Lillie, and K9TCC#5Lilly cells had high COX-2 protein expression. All 
five tested bladder TCC cell lines had high expression levels of COX-1 and NF-κB 
proteins.  
 
Axitinib and AB1010 inhibited cell proliferation and induced apoptosis in bladder 
TCC cells  
Both tested RTKIs, axitinib and AB1010, significantly reduced cell viability in a 
dose-dependent manner in all tested human and canine bladder TCC cell lines as is 
shown in Fig. 2.2. To further analyze the possible mechanism of axitinib and AB1010 in 
tested cells, we have selected h-5637 and K9TCC#1Lillie cells with the lowest and with 
the highest basal expression levels of PDGFRα and c-Kit receptors, respectively. The 
inhibition of cell viability in bladder TCC cells by AB1010 treatment positively correlated 
with the expression levels of PDGFRα and c-Kit receptors in tested cells. AB1010 
inhibited phosphorylation of c-Kit receptor in a dose-dependent manner causing the 
inhibition of cell viability in K9TCC#1Lillie cells (Fig. 2.5). No expression of 
phosphorylated PDGFRα (p-PDGFRα) was detected in either tested cell line after 
RTKIs treatment. Total PDGFRα protein expression was detected in K9TCC#1Lillie, but 
not in h-5637 cells (Fig. 2.5).  
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The effects of axitinib and AB1010 on cell apoptosis were evaluated using 
Annexin V-FITC staining by flow cytometry analysis and the caspase-3/7 activities 
assay. Doxorubicin (1 µM) treatment was used as a positive control for the detection of 
apoptosis (data not shown). After 24 h treatment, both 5 µM axitinib and 5 µM AB1010 
significantly increased apoptosis in h-5637 cells with a 3- and 1.5-fold increase, 
respectively, when compared to control (DMSO) as is shown in Fig. 2.3A. Axitinib 
treatment in h-5637 cells increased the number of apoptotic cells by 2-fold as compared 
to AB1010 treatment. In the K9TCC#1Lillie cells, both 5 µM axitinib and 5 µM AB1010 
significantly increased apoptosis by 1.8-fold when compared to the control (DMSO) 
group as is shown in Fig. 2.3B. Axitinib, but not AB1010, significantly increased 
Caspase 3/7 activity in h-5637 cells after 24 h treatment as shown in Figure 4A. Neither 
axitinib nor AB1010 statistically significantly increased the caspase-3/7 activity in 
K9TCC#1Lillie cells, as shown in Fig. 2.4A. The apoptosis induced by axitinib was also 
confirmed by upregulation of cleaved caspase-3 (cCaspase-3) and cleaved PARP 
(cPARP) in tested human 5637 cells by WB analysis (Fig. 2.4B, 2.4C). There were no 
detectable levels of cCaspase-3 expression in the h-5637 cells by AB1010 treatment 
(Figure 2.4B and 2.4C). Axitinib (10 µM) and AB1010 (10 µM) treatments increased 
cCaspase-3 expression when compared to control in the K9TCC#1Lillie cells by 3- and 
18-fold, respectively (Fig. 2.4B and 2.4C). Axitinib and AB1010 treatments increased 
cPARP expression by approximately 4-fold and 2-fold, respectively, when compared to 
control in h-5637 cells as shown by densitometry analysis of WB data in Fig. 2.4B and 
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2.4C. The cleavage of PARP was not detected after treatment with AB1010 or axitinib in 
K9TCC#1Lillie cells (Fig. 2.4B).  
 
Axitinib and AB1010 increased COX-2 expression in bladder TCC cells 
Both RTKIs, axitinib and AB1010, increased expression of COX-2 in h-5637 and 
K9TCC#1Lillie cells in dose-dependent manner (Fig. 2.6A). Based on the densitometry 
analysis of COX-2 protein expression in h-5637 cells, a 2-fold increase in COX-2 
expression was detected by both axitinib and AB1010 treatments when compared to the 
control. AB1010 treatment increased COX-2 protein expression in the K9TCC#1Lillie 
cells by 4-fold when compared to the control as shown in Fig. 5B. RTKI treatments had 
no effects on NF-κB expression in human 5637 cells (Figure 2.6A). AB1010 treatment 
increased NF-κB expression in a dose-dependent manner in the K9TCC#1Lillie cells. 
Axitinib and AB1010 significantly reduced the phosphorylation of Akt in human 5637 
cells in a dose-dependent manner as shown in Fig. 2.6A. In contrast, axitinib, but not 
AB1010, increased the phosphorylation of Akt in K9TCC#1Lillie cells (Fig. 2.6A and 
2.6B). Neither axitinib nor AB1010 treatments had effects on the phosphorylation of 
ERK1/2 in human 5637 or K9TCC#1Lillie cells (data not shown).  
 
NSAIDs inhibited AB1010-induced COX-2 expression in bladder TCC cells in vitro  
To test our hypothesis that inhibition of AB1010-induced COX-2 expression might 
lead to more effective inhibition of cell viability of bladder cancer cells by RTKIs, bladder 
TCC cells were co-treated with RTKIs and indomethacin (non-selective NSAID). Co-
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treatment of 5 µM AB1010 with 5, 10, 50, or 100 µM indomethacin was more effective 
inhibiting cell viability of K9TCC#1Lillie as compared to either treatment alone as is 
shown in Fig. 2.7A. Co-treatment of AB1010 and indomethacin was more effective in 
the inhibition of cell viability of K9TCC#1Lillie cells as compared to h-5637 cells (Fig. 
2.7A) due to higher expression of the target receptors, c-Kit and PDGFRα in 
K9TCC#1Lillie cells (Fig. 1A). In addition, indomethacin inhibited AB1010-induced COX-
2 expression in K9TCC#1Lillie cells as shown in Fig. 2.7B and 2.7C. Co-treatment of 
AB1010 with indomethacin did not affect the expression of NF-κB in either tested TCC 
cells (Fig. 2.7B). Co-treatment of AB1010 with indomethacin reduced Akt expression 
levels in K9TCC#1Lillie cells as shown in Fig. 2.7B. Co-treatment of AB1010 with 
indomethacin increased the cleaved PARP (cPARP) expression in h-5637 cells; 
however, no cPARP levels were detected in K9TCC#1Lillie cells Fig. 2.7B and 2.7C.  
 
NSAIDs inhibited AB1010-induced PGE2 production in K9TCC#1Lillie cells in vitro  
To evaluate the effects of AB1010 and indomethacin co-treatment on COX-2 
activity in h-5637 and K9TCC#1Lillie cells, released levels of PGE2 in media were 
measured by ELISA assay as shown in Fig. 2.8A and 2.8B. Indomethacin alone and in 
combination with AB1010 significantly inhibited PGE2 production in human 5637 cells. 
No significant change in PGE2 production was detected after AB1010 treatment in 
human 5637 cells (Fig. 2.8A). AB1010 treatment significantly increased PGE2 levels by 
1.75-fold in K9TCC#1Lillie cells. In addition, indomethacin inhibited AB1010-induced 
PGE2 production in K9TCC#1Lillie cells by 5-fold (Fig. 2.8B).  
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DISCUSSION 
 
Bladder TCC comprises 90% of all bladder cancer cases in the United State. 
Selection of treatment for patients diagnosed with bladder TCC depends on the grade 
(low or high) and invasiveness of the tumor. Surgery and conventional chemotherapy 
are used for low-grade TCC cases, but patients with advanced TCC rely on non-
conventional treatment options, such as radical surgery, novel therapeutics, and 
combination therapies (1). Axitinib is a US Food and Drug Administration-approved 
second-line RTKI therapy for patients with metastatic RCC (13). AB1010 is used for 
patients diagnosed with GIST and significantly improves prognostic outcomes (21). In 
this study, we have confirmed that AB1010 as compared to axitinib more efficiently 
inhibited cell viability of K9TCC#1Lillie cells through inhibition of the c-Kit receptor and 
inhibition of Akt signaling pathways. In addition, RTKIs increased apoptosis in both 
tested bladder TCC cells. RTKIs treatment caused increased expression of COX-2 in 
tested bladder TCC cells. Co-treatment of RTKIs with indomethacin inhibited cell 
viability and inhibited AB1010-induced COX-2 expression resulting in decreased PGE2 
production in tested bladder TCC cells. 
 Overexpression of multiple RTKs (PDGFRα/β, c-Kit, and VEGFR) and COX-2 is 
a common characteristic of bladder cancer (3-5,24,25). Basal expression profile of 
these RTKs indicate that tested h-TCC cells had lower expression of the RTKs (c-Kit 
and PDGFRα) when compared to the tested K9TCC cells (Fig. 2.1). Our results are 
consistent with a previously published study where low or no levels of mRNA or proteins 
of c-Kit were detected in human 5637 and T24 cells (50). Only UM-UC-3 cells have high 
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levels of PDGFRα mRNA, but no expression of c-Kit mRNA as detected by RT-PCR 
analysis (50). The activation of the PI3K/Akt pathway and loss of PTEN correlates with 
tumor progression and poor patient prognosis (51,52). The expression of 
phosphorylated Akt was not detected in either tested canine bladder TCC cells. Human 
T24 and UM-UC-3 cells have little to no detectable levels of COX-2 expression, 
respectively when compared to K9TCC#1Lillie and K9TCC#5Lilly cells (Fig. 2.1). Our 
results concur with previously published studies where no protein levels of COX-2 are 
detected in UM-UC-3 cells (53,54). 
 While AB1010 decreased cell viability and inhibited phosphorylation of c-Kit, 
increased levels of COX-2 and NF-κB expressions were detected in h-5637 and 
K9TCC#1Lillie cells (Fig. 2.6A). The increased COX-2 expression has been 
demonstrated in vitro and in vivo using several primary K9TCC cell lines, but the 
mechanisms, by which AB1010 increases COX-2 expression is still not well understood 
(39). We hypothesize that the increased COX-2 levels by RTKI could possibly lead to 
drug-resistance in COX-2 expressing tumors. To test our hypothesis, we evaluated the 
effects of co-treatment of AB1010 with indomethacin (NSAID) in h-5637 and 
K9TCC#1Lillie cells. Indeed, the co-treatment of AB1010 with indomethacin significantly 
reduced cell viability and COX-2 expression in h-5637 and K9TCC#1Lillie cells. Similar 
results have been demonstrated in patients with advanced pancreatic cancer, who 
received a combination therapy with AB1010 and gemcitabine compared to either 
treatment alone (18).  
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NSAIDs are commonly used for the treatment of inflammation as well as cancer 
(30,55).  We evaluated the effects of celecoxib (a COX-2 selective inhibitor; data not 
shown) and indomethacin (non-selective NSAID) on cell viability of bladder TCC cells. 
Our results indicated that co-treatment of AB1010 with indomethacin significantly 
inhibited cell viability in h-5637 and K9TCC#1Lillie cells (Fig 2.7A). Co-treatment of 
AB1010 with indomethacin decreased the phosphorylation of Akt (Ser473) in both 
bladder TCC cell lines, and decreased COX-1 and COX-2 protein expression levels in 
K9TCC#1Lillie cells (Fig 2.7B and 2.7C). The decreased levels of the AB1010-induced 
COX-2 was detected after co-treatment with indomethacin in both bladder TCC cell 
lines. Increased prostaglandins production positively correlates with COX-2 expression 
levels and progression of cancer (26-29). To validate whether AB1010 and 
indomethacin affect the activity of COX-2 in tested cells, we have measured the levels 
of PGE2 released into media 24 h after treatment of cells. AB1010 increased 
significantly the levels of COX-2 and production of PGE2 in K9TCC#1Lillie cells as 
shown in Fig. 2.8. Indomethacin inhibited the production of PGE2 in both tested cells 
and in addition, in co-treatment with AB1010 inhibited AB1010-induced COX-2 activity 
resulting in inhibition of PGE2 production in canine bladder TCC cells. Currently, co-
treatments of conventional chemotherapy agents with molecular targeted agents have 
been successfully applied for patients with drug-resistant cancers, including breast, 
lung, and colon cancer (56-58). COX-2/PGE2 signaling pathway exerts pro-oncogenic 
effects through activation of receptor tyrosine kinases in colorectal cancer (59) and non-
small cell lung cancer (60) that supports our finding that co-treatment of RTKIs and 
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NSAIDs might indicate better results for bladder cancer. Further experiments in vivo 
need to be conducted to confirm our findings of beneficial role of NSAIDs in co-
treatment with RTKIs in bladder TCC cells in vitro. In conclusion, drug-resistance is one 
of the many challenges in the treatment of bladder cancer. Thus, co-treatment of RTKIs 
with COX inhibitors might indicate better clinical outcomes for patients diagnosed with 
bladder cancer. 
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APPENDIX 
 
Figure 2.1 Expression profile of RTKs and COXs signaling pathway proteins in 
the human and primary canine bladder TCC by WB analysis. 
Cells were grown in the absence (-) or presence (+) of fetal bovine serum (FBS) for 
24 h. The expression of c-Kit, PDGFRα, p-ERK1/2, ERK1/2, p-Akt (Ser473), Akt1/2/3, 
COX-1, COX-2, and NF-κB proteins were evaluated by WB analysis. Actin was used as 
a loading control. Tested K9TCC cells had higher expression of RTK and COX proteins 
as compared to h-T24, h-5637, and h-UM-UC-3 cells.  
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Figure 2.2 Axitinib and AB1010 inhibited cell proliferation in bladder TCC cells in 
a dose-dependent manner.  
(A, B) Human UM-UC-3, T24, and 5637 and canine (C, D) K9TCC#1Lillie and 
K9TCC#5Lilly cells were treated with axitinib and AB1010 at dose of 0, 1, 5, and 10 μM 
for 48 h and cell viability was assessed by MTS assay. Both tested RTKIs inhibited cell 
viability of bladder TCC cells in a dose-dependent manner. Relative cell growth rates 
were normalized to the controls. Values represent mean ± S. E. of four replicates from 
three independent experiments; paired Student's t-test, *p < 0.05, **p < 0.01, and 
***p < 0.001. Symbols denote p-value for each cell line - * (UM-UC-3), Δ (T24), & (5637), 
‡ (Lillie), and + (Lilly). 
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Figure 2.3 Axitinib and AB1010 induced apoptosis in h-5637 cells.  
 (A) Human 5637 and (B) K9TCC#1Lillie cells were treated with 5 μM axitinib and 5 μM 
AB1010 for 24 h and cells were stained with Annexin V-FITC and propidium iodide 
followed by flow cytometry analysis. Percentage of apoptotic cells (positive for both 
Annexin V-FITC and PI staining) of treatment groups were normalized to the control 
(DMSO). Both axitinib and AB1010 significantly increased apoptosis in h-5637 and 
K9TCC#1Lillie cells. Values represent mean ± S.E. of two replicates from three 
independent experiments, paired Student’s t-test, *p < 0.05, **p < 0.01, and 
***p < 0.001. 
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Figure 2.3 
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Figure 2.4 Axitinib activates caspase3/7 and cleavage of caspase-3 in bladder 
TCC cells. 
Human 5637 and K9TCC#1Lillie cells were treated with 0, 1, 5, and 10 μM axitinib or 
AB1010 for 24 h. (A) Relative activities of caspase 3/7 were detected from cell lysates 
using the Caspase-Glo 3/7 luminescence assay. Both RTKIs treatments increased the 
caspase-3/7 activities in h-5637 cells, but not in K9TCC#1Lillie. Relative caspase-3/7 
activities were normalized to control, and values represent mean ± S.E. of two 
replicates of three independent experiments. Student's t- test, *p < 0.05, **p < 0.01, ***p 
< 0.001. (B) Axitinib treatment significantly increased the expression of cleaved PARP 
(cPARP) in h-5637 cells and cleaved caspase-3 (cCaspase-3) in both h-5637 and 
K9TCC#1Lillie cells as detected by WB analysis. The treatment of 10 µM AB1010 
significantly increased cCaspase-3 expression in K9TCC#1Lillie cells. Actin was used 
as a loading control. (C) Densitometry analyses of cCaspase-3 and cPARP protein 
levels from WB analysis were performed using VisionWorks analysis software. Values 
represent the mean ± S.E. of the measured densitometry of each protein band from 
three independent experiments. Paired Student’s t-test was used to compare axitinib 
and AB1010 treatments to control groups (*p < 0.05, **p < 0.01, ***p < 0.001).  
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Figure 2.4  
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Figure 2.4 (continued) 
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Figure 2.5 Axitinib and AB1010 inhibit phosphorylation of c-Kit in K9TCC#1Lillie 
cells.  
Human 5637, and K9TCC#1Lillie cells were treated with 0, 1, 5, and 10 μM axitinib and 
AB1010 for 24 h. The expression of p-c-Kit, c-Kit, p-PDGFRα, and PDGFRα proteins 
were determined by WB analysis. Actin was used as a loading control. No 
phosphorylated or total c-Kit expressions were detected in h-5637 cells. Both tested 
RTKIs inhibited phosphorylation of c-Kit in K9TCC#1Lille cells, but no p-PDGFRα levels 
were detected in either of the tested cell lines. 
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Figure 2.6 Axitinib and AB1010 increased COX-2 expression in a dose-dependent 
manner in tested bladder TCC cells by WB analysis.  
Figure 2.6 (continued) (A) Human 5637 and K9TCC#1Lillie cells were treated with 
axitinib and AB1010 at doses of 0, 1, 5, and 10 μM for 24 h. Actin was used as a 
loading control. Axitinib and AB1010 increased COX-2, but not NF-κB expression in h-
5637 cells. AB1010 increased COX-2 and NF-κB protein expression in a dose-
dependent manner in K9TCC#1Lillie cells. (B) Densitometry analysis of COX-2 and p-
Akt protein bands from WB analysis was performed using VisionWorks analysis 
software. Values represent the mean ± S.E. of the measured densitometry of each 
protein band from three independent experiments. Paired Student’s t-test was used to 
compare axitinib and AB1010 treatments to controls (*p < 0.05, **p < 0.01, ***p < 
0.001).  
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Figure 2.6 
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Figure 2.7 Co-treatment of AB1010 with indomethacin inhibited cell viability and 
AB1010-induced COX-2 expression in bladder TCC cells. 
(A) Human 5637 and K9TCC#1Lillie cells were treated either with 5 µM AB1010 (AB), 
or 5, 10, 50, and 100 μM indomethacin (Indo), or combination treatments AB + Indo. 
Cell viability of bladder TCC cells was determined by MTS assay, and relative cell 
growth rates were normalized to the controls. Co-treatment of AB1010 with 
indomethacin inhibited cell viability more effectively than either treatment alone in 
bladder cancer cells. Values represent mean ± S.E. of four replicates of three 
independent experiments; paired Student's t-test was used to compare the treatment to 
control groups, *p < 0.05, **p < 0.01, and ***p < 0.001. Student's t-test was used to 
compare AB + Indo to AB treatment groups, #p < 0.05, ##p < 0.01, and ###p < 0.001. 
Student's t-test was used to compare AB + Indo to Indo treatment groups, †p < 0.05, 
††p < 0.01, and †††p < 0.001. (B) Human 5637 and K9TCC#1Lillie cells were co-treated 
with 50 μM indomethacin and 5 μM AB1010, or each drug alone for 24 h. The 
expression of COX-1, COX-2, NF-κB, p-Akt (Ser473), Akt1/2/3, and cleaved PARP 
(cPARP) proteins were determined by WB analysis. Actin was used as a loading 
control. AB1010-induced COX-2 expression was inhibited by co-treatment with 
indomethacin in h-5637 and K9TCC#1Lillie cells. (C) Densitometry analysis of COX-2, 
p-Akt (Ser473), and cPARP protein bands from WB analysis was performed using 
VisionWorks analysis software. Values represent the mean ± S.E. of the measured 
densitometry of each protein band of three independent experiments. Paired Student’s 
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t-test was used to compare AB, Indo, and AB + Indo treatments to control groups, 
*p < 0.05, **p < 0.01, ***p < 0.001. 
91 
 
Figure 2.7 
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Figure 2.7 (continued) 
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Figure 2.7 (continued) 
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Figure 2.8 Co-treatment of AB1010 with Indo inhibited PGE2 levels produced by 
bladder TCC cells. 
(A) Human 5637 and (B) K9TCC#1Lillie cells were treated with 5 µM AB1010 (AB) and 
50 µM indomethacin (Indo) alone or in combination (AB + Indo). PGE2 levels in cell 
culture media collected 24 h after treatments were determined by ELISA. Indomethacin 
significantly reduced production of PGE2 by bladder TCC cells. Co-treatment of AB1010 
with indomethacin significantly decreased the AB1010-induced PGE2 levels produced 
by K9TCC#1Lillie cells. Values represent mean ± S.E. of six replicates of three 
independent experiments; paired Student’s t-test was used to compare treatments to 
the control groups, *p < 0.05 and ***p < 0.001. 
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CHAPTER III DETECTION OF CARCINOGEN-INDUCED COX-2-
EXPRESSING BLADDER CANCER BY FLUOROCOXIB A 
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Research article described in this chapter is a slightly modified version of an article that 
was prepared for submission to the American Association for Cancer Research journal, 
Cancer Research, by Jennifer Bourn, Robert Donnell, Jashim Uddin, Lawrence Marnett, 
and Maria Cekanova in October 2018. 
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ABSTRACT 
Conventional optical imaging technologies can detect advanced stages of 
bladder cancer; however, they have several limitations to detect bladder cancer at the 
early stages. Fluorocoxib A, a rhodamine-conjugated analog of indomethacin, is a novel 
fluorescent imaging agent that selectively targets cyclooxygenase-2 (Cox-2)-expressing 
cancers. In this study, we have used a well-established N-butyl-N-4-hydroxybutyl 
nitrosamine (BBN)-induced bladder cancer mouse model that strongly resembles 
human low-grade papillary and high-grade invasive urothelial carcinoma. We evaluated 
the ability of fluorocoxib A to detect the progression of carcinogen-induced bladder 
cancer in mice. Specific fluorocoxib A uptake by Cox-2-expressing bladder tumors was 
detected ex vivo using the IVIS Lumina imaging system. After ex vivo imaging, the 
progression of bladder carcinogenesis from normal urothelium to hyperplasia, 
carcinoma in-situ, and carcinoma with increased inflammation was assessed by H&E 
staining, increased Ki67, and decreased uroplakin-1A expression. The specific uptake 
of fluorocoxib A correlated with increased Cox-2 expression in bladder urothelial cells. 
In conclusion, fluorocoxib A detected the progression of bladder carcinogenesis in a 
mouse model with selective uptake in Cox-2-expressing bladder cancer in contrast to 
normal bladder urothelium where no fluorocoxib A uptake was detected. Fluorocoxib A 
is a novel, targeted optical imaging agent that could be applied for the detection of Cox-
2 expressing human bladder cancer. 
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INTRODUCTION 
Bladder cancer is the 6th most common type of cancer with an estimated 80,000 
newly diagnosed cases and 17,000 deaths per year in the United States (1). Bladder 
cancer incidence is 4 times higher in men than in women. The most common type of 
bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma, which 
accounts for over 90% of all bladder cancer cases in the United States. There are five 
stages of bladder cancer, with stage IV being the most advanced metastatic disease 
stage. Stages 0 and I are classified as non-muscle invasive bladder papillary carcinoma 
or flat carcinoma-in-situ (CIS) (NMIBC). Stages II – IV are more advanced stages, as 
the cancer has progressed through the muscle layer of the bladder wall, to surrounding 
local pelvic, and later to distal organs (muscle-invasive bladder cancer, MIBC) (2).  
Treatment management depends on whether the bladder cancer is NMIBC or 
MIBC. Currently the gold-standard treatment for MIBC is open radical cystectomy 
(ORC) followed by adjuvant platinum-based chemotherapy (3,4). Due to high 
complications and invasiveness of ORC, less invasive procedures have been explored, 
including a laparoscopic radical cystectomy (5,6). Adjuvant therapies include standard 
chemotherapy (mitomycin C or gemcitabine) or immunotherapy (Bacille Calmette-
Guérin) either alone or in combination (7-9). Standard treatment for NMIBC is a 
transurethral resection of bladder tumor (TURBT) followed by intravesical adjuvant 
therapy due to high risk of recurrence and progression of bladder cancer after 
procedure. The detection of bladder cancer at the early stages and more accurate 
detection of cancer during TURBT procedures is needed to improve patient outcomes.   
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Conventional optical imaging technologies can detect advanced stages of 
bladder cancer; however, they have several limitations to detect the early stages of 
bladder cancer (10). Newer technologies have been developed to significantly improve 
the quality of detection initial cancerous lesions and tumor margins TURBT procedures 
for prevention of disease recurrence and progression (11,12). There are four primary 
novel optical imaging technologies that have recently been investigated for clinical 
diagnostic use: fluorescence cystoscopy/photodynamic diagnosis (PDD), narrow band 
imaging (NBI), confocal laser endomicroscopy (CLE), and optical coherence 
tomography (OCT) (13,14).  Fluorescence cystoscopy/PDD and NBI are used as 
diagnostic tools to better visualize the tumors and optimize detection of early stage 
bladder cancer lesions. On the contrary, CLE and OCT are used to further character the 
detected lesions to improve accuracy in determining the grade and stage of the lesions. 
For the purposes of this study, we will focus on the fluorescence cystoscopy technology.  
White light cystoscopy (WLC) is the current standard of care for the detection of 
papillary or large growths lesions in the bladder. WLC has been used for several 
decades to detect bladder tumors but there are several limitations associated with WLC, 
including the inability to detect early-stage bladder cancer (CIS and low-grade tumors), 
as well as the inability to detect tumor margins during resection procedures leading to 
incomplete resection of the tumor (10). Fluorescent cystoscopy requires the 
administration of a contrast agent, which selectively binds to the cancer cells to improve 
visualization and differentiation of the cancer from normal tissue during resection 
procedures (15). Photodynamic diagnosis/blue-light cystoscopy (BLC) is an FDA-
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approved procedure, which requires the administration of 5-aminolevulinic acid (5-ALA) 
dye directly into the bladder (16,17). The dye is absorbed by the cancerous tissue and 
emits a red color under blue light allowing the better visualization of the tumor during the 
cystoscopy procedure. Previous studies indicates that BLC can detect bladder tumors 
more effectively than WLC, at both early and late stages (18-20).  
Cyclooxygenase-2 (Cox-2) is aberrantly expressed in bladder cancer and is one 
of the key proteins responsible for angiogenesis (21,22) and tumorigenesis 
(23,24). Increased Cox-2 expression has also been reported to be correlated with tumor 
grade in bladder cancer (25). The overexpression of Cox-2 in bladder cancer tissue be 
used as a biomarker for the detection bladder cancer. Fluorescently-labeled Cox-2 
inhibitors are suitable candidates for targeted optical, non-radioactive imaging due to 
their selective uptake by cancer cells. Fluorocoxib A is a rhodamine-conjugated analog 
of indomethacin that selectively targets Cox-2 in solid tumors (26). Fluorocoxib A has 
been validated previously for the detection of LPS-induced inflammation in a rat model 
(26) and in Cox-2-expressing cancer in vitro (27) and in vivo (28,29).   
In this study, we evaluated fluorocoxib A for detection of the early stages of Cox-
2-expressing, carcinogen-induced bladder cancer in immunocompetent mice. We 
validated the specificity of fluorocoxib A to detect both the early and late stages of Cox-
2-expressing bladder cancer in vivo. Our results indicate that fluorocoxib A can 
specifically detect Cox-2-expressing bladder cancer and has the potential to be used as 
an optical imaging agent during cystoscopy and TURBT procedures for human bladder 
cancer. 
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MATERIALS AND METHODS 
Antibodies and reagents 
The antibodies for UP1a (C-18, sc-15173) and actin (C-11, sc-1615) were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); antibody for Ki67 (SP6, 
ab16667) was purchased from Abcam Inc. (Cambridge, MA); antibody for Cox-2 (aa 
570-598, 160106) was purchased from Cayman Chemical (Ann Arbor, MI); and 
secondary anti-rabbit antibody was obtained from Cell Signaling Technology (Danvers, 
MA). All other chemicals and reagents were purchased from Thermo Fisher Scientific 
(Pittsburgh, PA), unless otherwise specified. 
 
Animals 
All animal experiments were performed in accordance with approved UT IACUC 
protocols. Thirty 5-wk old, female B6D2F1 mice (Taconic, Hudson, NY) were randomly 
divided into three groups (n=10/group). Group 1 served as the control group of mice that 
received only tap drinking water. The other two groups of mice were treated with BBN 
for 12 weeks (Group 2) and 18 weeks (Group 3). Carcinogen N-butyl-N-(4-hydroxybutyl) 
nitrosamine (BBN) was obtained from Sigma-Aldrich (St. Louis, MO) and was supplied 
ad libitum at 0.05% in drinking water to mice for 12 or 18 weeks, respectively.  
 
Fluorocoxib A uptake detection by IVIS Lumina optical imaging system 
After the treatment with BBN at 12 and 18 weeks, respectively, fluorocoxib A 
(1mg/kg) was administered subcutaneously (SC). Specific fluorocoxib A uptake was 
104 
 
detected 4 h after administration by whole body imaging performed using the Xenogen 
IVIS Lumina optical imaging system with DsRed filters with excitation 500 to 550 nm, 
emission 575 to 650 nm, and background 460 to 490 nm. After imaging, the mice were 
sacrificed, tissues were dissected, and imaged ex vivo. The obtained total flux (p/s) and 
average radiant efficiency [p/s/cm2/sr]/ [µW/cm²] of labeled regions of interest of 
dissected bladder and other tissues (blood, kidney, liver, lung, heart, muscle, spleen, 
pancreas, and fat) were evaluated. Tumor-to-noise ratio (TNR) values were generated 
by dividing the average radiant efficiency of the bladder tissue to blood as the 
background fluorescence (noise). After imaging, each dissected bladder was divided 
into three pieces. One piece of bladder was fixed in 10% neutral buffered formalin for 
histology and immunohistochemistry (IHC) analysis. The second piece of bladder was 
placed into O.C.T. media for immunofluorescence (IF) detection of fluorocoxib A uptake 
by neoplastic tissue using fluorescence microscopy and the third piece of bladder was 
kept in RNAlater solution and stored at -80°C until Western blotting (WB) analysis was 
performed. 
 
Immunohistochemistry  
Dissected tissues from mice were formalin-fixed, paraffin-embedded, and 
sectioned at 7 μm. Hematoxylin and eosin (H&E) was performed following standard 
histological staining protocol. The IHC staining was performed as described previously 
(29). After de-paraffinization, the antigen retrieval using sodium citrate pH 6.0 was 
performed for 20 min in antigen retriever (Electron Microscopy Sciences, Hatfield, PA). 
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The blocking of endogenous peroxidase activity was performed by 3% H2O2 in 50% 
methanol for 5 min, followed by the blocking of non-specific signal using protein block 
solution (BioGenex, Fremont, CA). Tissues were incubated with primary antibodies 
(Ki67, UP1a, and Cox-2), followed by the incubation with the specific biotinylated 
secondary antibodies, streptavidin/HRP detection system, and visualized by 3,3’-
diaminobenzidine (DAB) staining. Nuclei were counter-stained with hematoxylin and 
slides were cover-slipped and evaluated using a Leitz DMRB microscope. The images 
were captured by a DP73 camera attached to microscope using CellSens Standard 
software (Olympus, Pittsburgh, PA). 
 
Western blotting analysis 
The tissue samples were lysed in ice-cold RIPA buffer supplemented with a 
protease and phosphatase inhibitors cocktail (1 mM PMSF; 1 μg/ml aprotinin; 1 μg/ml 
leupeptin; 5 mM Na3VO4; 5 mM NaF) and briefly sonicated on ice. Protein 
concentrations were measured using Pierce® BCA protein assay (Thermo Scientific, 
Rockford, IL). Equal amount of proteins (50 μg) were loaded onto SDS-PAGE gels and 
transferred to nitrocellulose membranes. After blocking, the membranes were incubated 
with primary antibodies overnight at 4˚C, followed by incubation with horseradish 
peroxidase-conjugated secondary antibodies (1: 3,000 dilution) for 1 h at room 
temperature. The immuno-reactive bands were visualized using the ECL prime 
chemiluminescence system (GE Healthcare Life Sciences, Marlborough, MA) and the 
images were captured using the BioSpectrum® 815 imaging system (UVP, Upland, 
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CA). Densitometry analysis was performed using the VisionWorks acquisition and 
analysis software (UVP). 
 
Statistical analysis 
Statistical analysis was conducted using the paired Student's t-test to establish 
significant differences among treatment groups. Results were considered statistically 
significant at *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
RESULTS 
BBN-induced bladder cancer mouse model 
Thirty female 5-week old B6D2F1 mice were randomly divided into three groups 
(n=10/group). Group 1, served as the control and received only tap water for 18 weeks 
(Group 1 – 18wks H2O). The other two groups were exposed to the carcinogen, BBN for 
12 weeks (Group 2 – 12wks BBN) and 18 weeks (Group 3 – 18wks BBN). BBN was 
administered ad libitum at 0.05% in drinking water (Fig. 3.1A). Body weight of each 
mouse was recorded weekly and average weight per mouse (g) is presented in Fig. 
3.1B. BBN had no adverse effect on the growth of the mice over time as no remarkable 
differences in body weight was observed between groups. Water consumption (ml) was 
recorded weekly and compared between groups (Fig. 3.1C). There was significant 
increase in water consumption for Group 2 and Group 3 when compared to the control 
(Group 1).  Values represent mean ± standard error of each weekly recording from n=10 
mice; paired Student's t-test, ***p < 0.001.  
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Fluorocoxib A uptake by BBN-induced bladder cancer in vivo 
After BBN exposure over time, fluorocoxib A was administered subcutaneously (1 
mg/kg) followed by imaging of the mice. Imaging of the whole body and dissected 
tissues was performed using the Xenogen IVIS Lumina optical imaging system to detect 
fluorocoxib A uptake. The control group (Group 1 – 18wks H2O) was imaged at the 
same time as Group 3 (18wks BBN). After euthanasia, whole body photographs were 
obtained of the individual mice bladders (Fig 3.2A). As shown by the representative 
images, the bladders from mice in Group 2 and Group 3 were larger when compared to 
the control group mice (Group 1). The dissected tissues were photographed and 
imaged ex vivo (Fig. 3.2B). Higher uptake and increased intensity of fluorocoxib A was 
observed in Group 3 when compared to the Group 1 (control) and Group 2 as shown in 
Fig. 3.2C. No fluorocoxib A uptake was detected in the bladders from control mice 
(Group 1). Moderate uptake of fluorocoxib A was observed in both the liver and muscle 
tissues of all three groups. Obtained average radiant efficiencies ([p/s/cm²/sr]/[µW/cm²]) 
of each organ were plotted (Fig. 3.2D). There is an observed increase in average 
radiant efficiency in the bladders of mice from Group 3 when compared to the control, 
indicating an increased uptake of fluorocoxib A. Average radiant efficiencies values of 
bladders were normalized to blood (TNR) and fold changes in fluorocoxib A uptake were 
plotted (Fig. 3.2E). The significant 1.8- and 3.2-fold increase in fluorocoxib A uptake was 
observed in bladders from mice in Group 2 and 3, respectively, when compared to 
bladders from untreated mice (Group 1).  
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Progression of bladder carcinogenesis by BBN 
The histopathology of the dissected bladder tissues was assessed by H&E and 
IHC staining for detection of Ki67 and uroplakin-1A (UP1a) expression (Fig. 3.3). The 
BBN-induced bladder cancer progression from normal urothelium (Group 1) to 
hyperplasia, (Group 2) and to invasive carcinoma (Group 3) with presence of intensive 
inflammation in bladder of the mice as confirmed by H&E staining (left). The histological 
analysis of the H&E sections of the bladder tissue from each mouse was recorded to 
quantify the prevalence of BBN-induced inflammation, hyperplasia, CIS, and carcinoma 
among the experimental groups (Table 3.1). Mice from Group 2 (12wks BBN) and 
Group 3 (18wks BBN) had increased incidence of inflammation, hyperplasia, and 
bladder carcinoma when compared to mice from Group 1 (control). Tables 3.2 and 3.3 
provide the description of the scoring summary used for histology evaluation of the 
bladder tissues and the individual evaluation of each mouse from all treatment groups. 
The progression of bladder carcinogenesis was also confirmed by the presence of 
increased expression of Ki67 expressing cells in bladder carcinomas from mice treated 
with BBN – Group 2 and Group 3 (middle). In addition, UP1a, a protein that is highly 
expressed in normal bladder urothelium (Group 1), was downregulated in BBN-induced 
bladder cancer (Group 2 and 3) as confirmed by IHC analysis (right). Fluorocoxib A 
uptake correlated with presence of neoplastic lesions in the bladders of mice exposed to 
BBN compared to mice in the control group. 
 
 
109 
 
Upregulation of Cox-2 by BBN in bladder carcinoma 
The upregulation of Cox-2 in BBN-induced bladder cancer was detected by IHC 
(Fig. 3.4A) and WB analysis (Fig. 3.4B). Bladder carcinomas in mice from Group 3 
(n=10; 18wks BBN) had significantly higher Cox-2 expression when compared to normal 
urothelium in mice from Group 1 (n=7; control) and bladder inflammation and 
hyperplasia in mice from Group 2 (n=9; 12wks BBN). This result was also confirmed by 
WB analysis of the dissected bladder tissues from each group. The tissues from Group 
2 and Group 3 had higher Cox-2 expression when compared to the control (Group 1) 
where there was no detectable Cox-2 expression. Densitometry analysis of Cox-2 
protein bands from WB analysis was performed using VisionWorks acquisition and 
analysis software (UVP) (Fig. 3.4C). There is a significant 2.7- and 8.6-fold increase in 
Cox-2 expression for Group 2 and Group 3, respectively, when compared to Group 1. 
Paired Student’s t-test was used to compare the upregulation of Cox-2 expression in 
BBN-treated groups (Group 2 and 3) with control group (Group 1), *p < 0.05. The 
specific uptake and increased intensity of fluorocoxib A (Fig. 3.2) in carcinogen-induced 
bladder cancer of mice exposed to BBN correlated with the progression of bladder 
carcinogenesis (Fig. 3.3) and with the increased Cox-2 expression (Fig. 3.4).  
 
DISCUSSION 
Bladder cancer is the 6th most common type of cancer in the United States, with 
higher incidence in men than in women and is one of the most expensive malignancies 
to treat (1). Current treatment options for patients diagnosed with bladder cancer is 
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dependent on the stage of cancer. The standard treatment regime for bladder cancer is 
typically a TURBT procedure followed by adjuvant therapy (4). There is a high risk of 
recurrence and progression following TURBT procedures driving the need for improved 
diagnostic tools to aid in improved detection and prevention of bladder cancer 
recurrence. This study demonstrates the visualization of Cox-2-expressing, carcinogen-
induced early and late stage bladder cancer in mice in vivo by use of the novel optical 
imaging agent, fluorocoxib A.  
There are several models currently available for the study of bladder 
carcinogenesis, including genetically altered rodents that can develop spontaneously 
occurring tumors or the use of carcinogens to induce tumors in the rodents (30,31). 
Nitrosamines are a highly carcinogenic group of compounds that have been known to 
induce hepatic, gastric, and bladder cancer (32,33). The most common nitrosamine 
used for the induction of bladder cancer is N-butyl-N-(4-hyrdoxybutyl) (BBN),  which is 
found in cigarette smoke (34). After ingestion, BBN is metabolized by the liver into 
several metabolites, which are further excreted from the body through urine. In the 
bladder, the metabolites come in contact with the urothelium and initiate the 
carcinogenic process resulting in DNA damage and development of both the early 
(hyperplasia and CIS) and late stages (MIBC) bladder cancer in immunocompetent 
mice (35,36). Bladder cancer in mice develops relatively early after BBN exposure with 
early-stage tumors developing after 12 weeks of exposure and late-stage tumors 
presenting after 18 weeks of exposure. To ensure the development of heterogeneous 
bladder tumor phenotypes, 30 B6D2F1 mice were randomly divided into 3 groups (n=10 
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mice/group). BBN is administered orally either in drinking water or by oral gavage at 
doses that range from 0.01-0.05% (37). As shown in Fig. 3.1A, 0.05% BBN was 
administered ad libitum in drinking water for 12 (Group 2) and 18 (Group 3) weeks. 
Despite significant increase in water consumption by the treatment groups compared to 
the control group, the prevalence of inflammation and tumor development within the 
treatment groups was not known until after euthanizing the mice from each group and 
histopathological analysis was performed. 
Fluorescence cystoscopy is an attractive modification to WLC procedures 
because this technique allows for the visualization of the accumulation of the contrast 
agent in the cancerous cells. Previous studies indicate better diagnostic outcomes for 
patients with NMIBC using fluorescent cystoscopy than with WLC alone (38,39). There 
are several limitations to this method; however, including rapid photo-bleaching during 
the cystoscopy procedure, high false-positive rate (up to 30%), and this technique has 
not been approved for repeat procedures in patients as there is limited data to support 
how patients will react to the contrast agent after repeat exposures (40,41). The 
photosensitizing agent administered before the cystoscopy procedures, while it is 
selective for the increased blood flow to the tumor sites, the agent is not directly 
selective for the cancer cells. Increased inflammation following intravesical adjuvant 
therapies has been demonstrated to be correlated with false-positive rates of detection 
after fluorescent cystoscopy procedures (40,42). The non-selective properties of the 
contrast agent can contribute to an increase in false positive detection rates. These 
limitations drive the need for a selective contrast agent that will bind directly to the 
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cancer cells and decrease the false-positive rates while improving the detection of the 
neoplastic lesions in the bladder. The development of targeted optical imaging agents 
for preclinical and clinical studies has shifted the direction of current imaging research to 
further improve diagnostic detection methods for patients diagnosed with cancer to 
better patient prognosis. Fluorocoxib A, which is a Cox-2-selective imaging agent, is a 
prime candidate for the detection of bladder cancer during cystoscopy procedures due 
to its highly stable properties, ease of administration, and non-toxic effects. Previous 
preclinical studies indicate that fluorocoxib A has demonstrated to be highly specific and 
selective for detecting Cox-2-expressing inflammation and cancers, including bladder 
and non-melanoma skin cancer (26-29). 
In this study following BBN exposure, fluorocoxib A was administered 
subcutaneously followed by ex vivo imaging of the BBN-induced bladder tumors in 
mice. Higher uptake and increased intensity of fluorocoxib A was observed in Group 3 
(18wks BBN) when compared to Group 1 (control) and Group 2 (12wks BBN), which 
also correlated with the progression of bladder cancer (Fig. 3.2C & D). Moderate uptake 
of fluorocoxib A was observed in both the liver and muscle tissue of all three groups. 
Non-specific uptake in these tissues in indicative of the breakdown of fluorocoxib A in 
the mice (26). The significant 1.8- and 3.2-fold increase in fluorocoxib A uptake was 
observed in bladders from mice in Group 2 and 3, respectively, when compared to the 
bladders from untreated mice (Group 1) (Fig. 3.2E). These results demonstrate the 
specificity of fluorocoxib A uptake by the cancerous bladder tissue when compared to 
normal urothelium (Group 1) where no fluorocoxib A uptake was recorded. Furthermore, 
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the range of fluorocoxib A uptake between the groups indicates the ability of fluorocoxib 
A to detect different stages of bladder tumors, including early and late stage tumors. 
The BBN-induced bladder cancer progression from normal urothelium (Group 1), 
to inflammation and hyperplasia (Group 2), and to invasive carcinoma (Group 3) in mice 
was confirmed by H&E staining (Fig. 3.3 - left). As shown in table 1, all bladder tissue 
from mice in Group 2 (12wks BBN) displayed signs of inflammation and the majority had 
signs of early stage bladder cancer (hyperplasia and CIS). All bladder tissue from mice 
in Group 3 (18wks BBN), displayed signs of inflammation and hyperplasia as well as 
developed bladder carcinomas. These results demonstrate a heterogeneous tumor 
population induced by BBN exposure and are consistent with previous BBN studies 
(32,34,36). Ki67 is a cellular marker associated with proliferation and is present in all 
cell cycle phases. The fraction of Ki67 positive tumor cells is often correlated with 
patient prognosis and aids in determining clinical course of treatment. The progression 
of bladder carcinogenesis was confirmed by the presence of increased expression of 
Ki67 positive cells in bladder tissues from mice treated with BBN – Group 2 and Group 
3 (Fig. 3.3 - middle). Uroplakin-1A (UP1a) is a member of a group of cell-surface 
proteins and is highly expressed in normal bladder urothelium (Group 1). UP1a plays a 
role in maintaining normal urothelium tissue and aids in tumor suppression. In this 
study, UP1a expression is downregulated in BBN-induced bladder cancers (Group 2 
and 3) as confirmed by IHC analysis (Fig. 3.3 - right). The downregulation of UP1a 
indicates a loss of normal urothelium and change in morphology of the bladder tissues 
as the cancer progresses. The fluorocoxib A uptake correlates with the progression of 
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neoplastic lesions in the bladder, higher uptake in the treatment Groups 2 and 3, when 
compared to the control, Group 1. 
The upregulation of Cox-2 expression by BBN in bladder tumors was confirmed 
by IHC and WB analysis (Fig. 3.4A & B). Developed bladder carcinomas in mice from 
Group 3 had significantly higher Cox-2 expression when compared to normal urothelium 
in mice from Group 1 and bladder inflammation and hyperplasia in mice from Group 2. 
There is a significant 2- and 8-fold increase in Cox-2 expression for Group 2 and Group 
3, respectively, when compared to Group 1 (Fig. 3.4C). These results are consistent 
with the protein expression profile of Cox-2, where Cox-2 is not expressed in normal 
tissue but is easily inducible during periods of inflammation and cancer. Cox-2 plays a 
key role in modulating cellular proliferation, apoptosis, and tumor invasion. The 
upregulation of Cox-2 may also be indicative of poor patient prognosis. These results 
also correlate with the increased uptake of fluorocoxib A in the bladders of mice that 
were positive for inflammation, hyperplasia, and developed carcinomas. Taken together, 
the results of this study demonstrate the selective and specific properties of fluorocoxib 
A uptake in Cox-2-expressing tissues.  
In conclusion, the specific uptake and increased intensity of fluorocoxib A (Fig. 
3.2) in the carcinogen-induced bladder cancers of mice treated with BBN in vivo 
correlated with the progression of bladder carcinogenesis (Fig. 3.3) and with the 
increased Cox-2 expression (Fig. 3.4). Currently, conventional imaging technologies for 
the detection of bladder cancer have several limitations, primarily lacking the ability to 
detect early stage bladder cancer and poor visualization of tumor margins during 
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resection procedures. The development of novel techniques and imaging agents, such 
as fluorocoxib A, can greatly improve patient prognosis by aiding in both the diagnostic 
and treatment procedures. Further molecular imaging studies need to be conducted to 
evaluate fluorocoxib A during cystoscopy procedures in different animal models but 
here we have demonstrated the ability of fluorocoxib A to detect both early stage and 
late stage Cox-2-expressing bladder cancer using a carcinogen-induced bladder cancer 
mouse model.  
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APPENDIX  
 
Table 3.1 Prevalence of BBN-induced inflammation, hyperplasia, carcinoma in 
situ (CIS), and carcinoma among treatment groups. 
 
 
 
Inflammation 
 
Hyperplasia CIS Carcinoma 
 
Group 1 – 
18wks H2O 
 
2/8 2/8 0/8 0/8 
 
Group 2 – 
12wks BBN 
 
9/9 5/7 2/7 2/7 
 
Group 3 – 
18wks BBN 
 
10/10 10/10 3/10 6/10 
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Table 3.2 Description of scoring summary used for the histology evaluation of 
bladder tissue from mice.  
 Score Description 
Inflammation 
 
0 
 
no presence of inflammation 
1 low presence of inflammatory cells 
2 moderate presence of inflammatory cells 
3 high presence of inflammatory cells 
N, L, P, M neutrophils, lymphocytes, plasma cells, macrophages 
Hyperplasia 
0 no presence of hyperplasia (less than 2 cells in layer) 
1 low hyperplasia (between 3-5 cells in urothelial tissue) 
2 severe hyperplasia (more than 5 cells in layer) 
D, F, M Diffuse, focal, multi-focal 
Carcinoma in 
situ (CIS) 
No no CIS present 
Yes CIS present 
Carcinoma 
No no carcinoma present 
Yes carcinoma present 
AC, SCC, 
TCC 
Adenocarcinoma, squamous cell carcinoma, 
transitional cell carcinoma 
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Table 3.3 Histology evaluation of bladder tissue from individual mice among 
treatment groups. 
 Mouse Inflammation Hyperplasia 
Carcinoma 
in situ 
Carcinoma 
Group 1 – 
18wks H2o 
1 1 (L) 0 0 0 
2 0 1 (F) 0 0 
3 3 (LF) 1(F) 0 0 
4 0 0 0 0 
5 0 0 0 0 
6 0 0 0 0 
7 0 0 0 0 
8† - - - - 
9† - - - - 
10 0 0 0 0 
Group 2 – 
12wks BBN 
1* - - - - 
2 2 (NPL) 0 0 0 
3 1 (NL) 1 (M) 0 0 
4 3 (LP) no epithelium 
no 
epithelium 
no 
epithelium 
5 3 (LP) no epithelium 
no 
epithelium 
no 
epithelium 
6 2 (NPL) 2 (L) yes yes 
7 2 (LP) 1 (M) 0 0 
8 1 (L) 
minimal 
epithelium 
0 0 
9 1 (NPL) 1 (M) 0 0 
10 1 (NLP) 1 (M) yes yes 
Group 3 – 
18wks BBN 
1 1 (LPN) 1 (D) yes 0 
2 3 (PNL) 2 (M) yes yes 
3 2 (LP) 1 (+2) 0 0 
4 3 (LN) 1 (+2) 
yes/ 
hyperplasia 
0 
5 2 (L) 1 0 yes 
6 2 (L) 1 0 yes 
7 2 (LN) 1 0 yes 
8 2 (LN) 1 (+2) 0 yes 
9 3 (LNP) 1 0 yes 
10 2 (LN) 1 (D) 0 0 
†No bladder tissue for histology evaluation 
*Mouse died before the end of experiment 
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Figure 3.1 BBN-induced bladder cancer mouse model. 
(A) B6D2F1 female mice were exposed to N-butyl-N-(4-hydroxybutyl) nitrosamine 
(BBN) in drinking water for 12 weeks (n=10; Group 2) and 18 weeks (n=10; Group 3). 
Mice without BBN for 18 weeks (n=10; Group 1) served as a control. After 12 and 18 
weeks, mice were injected subcutaneously with Fluorocoxib A (1mg/kg) and imaged 
using the IVIS Lumina optical imaging system. (B) Body weight (g) measurements were 
recorded weekly to monitor the effect BBN consumption on growth. No remarkable 
differences in body weight among the different groups was seen. (C) Daily drinking 
water consumption (ml) per mouse was measured. There is a significant increase in 
water consumption for Group 2 and Group 3 when compared to the control (Group 1). 
Values represent mean ± standard error of each weekly body weight (g) and water 
consumption (ml) recording from n=10 mice; paired Student's t-test, ***p < 0.001. 
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Figure 3.1 
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Figure 3.2 Fluorocoxib A uptake by BBN-induced bladder cancer in vivo. 
After 4 h fluorocoxib A uptake, whole body and organ imaging was performed using the 
IVIS Lumina optical imaging system. (A) After sacrificing mice, representative images of 
mice bladders were obtained. (B) The dissected organs were photographed and imaged 
ex vivo. Organs from left to right: Row 1 - bladder, heart, lung; Row 2 - kidney, muscle, 
blood; Row 3 - liver, pancreas & spleen, fat. (C) Higher uptake and increased intensity 
of fluorocoxib A was observed in Group 3 when compared to the Group 1 (control). (D) 
Obtained average radiant efficiencies ([p/s/cm²/sr] / [µW/cm²]) of each organ were 
plotted. (E) Average radiant efficiency values of bladders were normalized to blood 
(TNR) and fold changes in fluorocoxib A uptake were plotted. The 1.8- and 3.2-fold 
increase in fluorocoxib A uptake was observed in bladders from mice in Group 2 and 3, 
respectively, when compared to the bladder from untreated mice. Paired Student’s t test 
was used to compare the increase in fluorocoxib A uptake in BBN-exposed groups 
(Group 2 and 3) with control group (Group 1), ***p < 0.001. 
 
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 
 
A B C 
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Figure 3.3 Progression of bladder cancer by BBN. 
The BBN-induced bladder cancer progression from normal urothelium (Group 1), to 
hyperplasia, and carcinoma in situ (Group 2 and 3), and to invasive carcinoma (Group 2 
and 3) with increased inflammation of bladder in mice was confirmed by H&E staining 
(left). The progression of bladder carcinogenesis was confirmed by increased 
expression of Ki67 in bladder from mice exposed to BBN (middle). In addition, 
uroplakin-1A, a protein that is highly expressed in normal bladder urothelium (Group 1), 
was downregulated in BBN-induced bladder cancers (Group 2 and 3) as confirmed by 
IHC analysis (right). Brown color is positive staining for tested proteins. Images taken by 
Leitz DMRB microscope, objective 10x, scale bar 100µm. C – carcinoma; CIS – 
carcinoma in situ; H – hyperplasia; I - Inflammation; U - Normal urothelium.  
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Figure 3.3 
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Figure 3.4 Upregulation of Cox-2 by BBN in bladder carcinoma. 
The upregulation of Cox-2 in BBN-induced bladder carcinoma was detected by (A) IHC 
and (B) WB analysis. Bladder carcinoma in mice from Group 3 (n=10; 18wks BBN) had 
higher Cox-2 expression when compared to normal urothelium in mice from Group 1 
(n=7; control) and bladder hyperplasia in mice from Group 2 (n=9; 12wks BBN). The 
higher Cox-2 expression in Group 3 correlates to higher fluorocoxib A uptake. Brown 
color is positive staining for tested protein expression. Images taken by Leitz DMRB 
microscope, objective 10x, scale bar 100µm. Actin was used as a WB loading control. 
(C) Densitometry evaluation of Cox-2/actin protein bands from WB analysis was 
performed using VisionWorks acquisition and analysis software (UVP). Paired Student’s 
t-test was used to compare the upregulation of Cox-2 expression in BBN-exposed 
(Group 2 and 3) with control group (Group 1), *p < 0.05. 
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Figure 3.4 
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CHAPTER IV DETECTION OF RECEPTOR TYROSINE KINASE 
INHIBITORS-INDUCED COX-2 UPREGULATION IN BLADDER CANCER 
BY FLUOROCOXIB A 
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Research article described in this chapter is a slightly modified version of an article that 
was prepared for submission to the World Molecular Imaging Society journal, Molecular 
Imaging and Biology, by Jennifer Bourn, Sony Pandey, Jashim Uddin, Lawrence 
Marnett, and Maria Cekanova in November 2018. 
 
Detection of receptor tyrosine kinase inhibitor-induced COX-2 upregulation in bladder 
cancer by fluorocoxib A. 
Jennifer Bourn, Sony Pandey, Jashim Uddin, Lawrence Marnett, and Maria Cekanova 
Molecular Imaging and Biology (Manuscript in Progress) 
 
In this paper, “our” or “we” refers to my co-authors and me. My contribution to this 
manuscript includes: 1) Compiling and interpretation of literature, 2) Providing 
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ABSTRACT 
 
Purpose: A challenge with targeted therapies is the activation of alternative pro-survival 
signaling pathways, such as COX-2 upregulation, resulting in acquired drug resistance. 
COX-2 is overexpressed in bladder cancer cells, making it an attractive target for the 
detection and treatment of cancer. Fluorocoxib A is an optical imaging agent that 
selectively targets COX-2 which can be used for the detection and monitoring of bladder 
cancer. In this study, we evaluated the effects of RTKIs on bladder cancer cell lines in 
vitro and in vivo. We also evaluated the ability of fluorocoxib A to detect the response to 
targeted therapies in vivo.  
Procedures: The effects of RTKIs on bladder cancer cells in vitro were analyzed by 
MTS and WB analysis. The effects of RTKIs in vivo were evaluated using the 
K9TCC#5Lilly xenograft tumor model and fluorocoxib A uptake was detected using the 
IVIS Lumina imaging system. COX-2 expression in the K9TCC#5Lilly xenografts was 
confirmed by IHC and WB analysis.  
Results: Despite inhibiting cell viability, AB1010 and imatinib, increased COX-2 
expression in bladder TCC cells in vitro. Specific uptake of fluorocoxib A correlated with 
the RTKI-induced COX-2 upregulation in the K9TCC#5Lilly xenografts in vivo. 
Conclusions: These results indicate that fluorocoxib A can be used for monitoring the 
responses to targeted therapies in patients diagnosed with COX-2-expressing bladder 
cancer. 
Keywords: Bladder cancer, RTKIs, COX-2, targeted therapies response, optical 
imaging, fluorocoxib A 
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INTRODUCTION 
Bladder cancer is the 6th most common type of cancer in the United States and 
one of the most expensive malignancies to treat due to high recurrence rates and lack 
of improved treatment options over the past several decades (1-3). In 90% of all cases, 
bladder cancer originates from the epithelial lining of the bladder known as the 
urothelium. This type of bladder cancer is known as transitional cell carcinoma (TCC) or 
urothelial carcinoma (4). Early detection of bladder cancer proves to provide better 
prognostic outcomes for patients diagnosed with bladder cancer (5). Despite 
demonstrating the need for improved diagnostic screening, prevention, and treatment 
options, bladder cancer still remains one of the most commonly diagnosed malignancies 
in the United States (6). This drives the need for improved detection and novel 
therapeutic options for patients diagnosed with both non-muscle invasive bladder 
cancer (NMIBC) and muscle invasive bladder cancer (MIBC).  
 Receptor tyrosine kinases (RTKs) mediate key signaling pathways involved in 
cell proliferation, differentiation, survival, and cell migration (7-8). Mutations of RTKs can 
affect the expression of downstream signaling pathways such as the MAP kinase, 
PI3K/Akt, and cyclooxygenase (COX)-2 pathways, resulting in aberrant cell function 
which plays an important role in a number of biological processes, including the 
progression of cancer (9). RTKs, such as the c-Kit receptor, platelet derived growth 
factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), are 
overexpressed in many types of cancer, including bladder cancer (10-12). Inhibitors of 
RTKs (RTKIs) are therefore used as targeted therapy options for patients diagnosed 
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with cancer that overexpress RTKs to inhibit auto-phosphorylation and downstream 
signal transduction, halting tumor progression (13-14). For many decades, kinases have 
been extensively studied as potential drug targets and to date, 38 RTKIs have been 
FDA-approved for the treatment of cancer, including imatinib (Gleevec) (15-16). There 
are even more RTKIs under development in pre-clinical research and clinical trial 
phases, including AB1010 (Masitinib or Masivet) (17).  
Imatinib is a potent and selective inhibitor of the c-Kit (IC50 = 100 nm) and 
PDGFRα/β (IC50 = 100 nm) receptors (18-19). It currently is used as a first-line therapy 
option for treatment of chronic myeloid leukemia (CML) and for advanced stage 
gastrointestinal stromal tumors (GIST) (20-22). AB1010 is a novel RTKI that also 
selectively targets the c-Kit (IC50 = 200 nm) and PDGFRα/β (IC50 = 540 nm and 800 nm, 
respectively) receptors (17). AB1010 is approved in Europe to be used as a treatment 
option for canine mast cell tumors and has been investigated for the treatment of 
patients diagnosed with GIST and pancreatic cancer, alone and in combination with 
chemotherapy agents (23-28). Both imatinib and AB1010 are well-tolerated with few 
side effects, unlike chemotherapeutic agents. A common challenge associated with 
targeted therapies is the activation of alternative pro-survival signaling pathways, such 
as the COX-2 pathway, resulting in acquired drug resistance. Previous studies indicate 
treatment with chemotherapeutic agents and even targeted therapies, such as RTKIs, 
increased COX-2 expression in bladder cancer cells, glioma cancer stem cells (CSCs), 
and oral squamous cell carcinoma cells in vitro (29-32). This drives the need for the 
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early detection and monitoring of responses to targeted therapies for patients diagnosed 
with bladder cancer to improve prognostic outcomes. 
 During periods of inflammation and cancer, COX-2 is one of the key proteins 
responsible for promoting angiogenesis, cell proliferation, and inhibiting apoptosis (33-
36). COX-2 is overexpressed in many types of cancer, including bladder cancer, and is 
often an indicator of poor patient prognosis (37). Overexpression of COX-2 in bladder 
cancer tissue can therefore be used as a biomarker for the treatment and detection of 
bladder cancer. Conventional optical imaging modalities, primarily cystoscopy, for 
bladder cancer have several limitations, including poor ability to detect bladder cancer 
at the early stages and poor differentiation of tumor margins during resection 
procedures (38). To improve diagnostic imaging tools during cystoscopy procedures, a 
key focus in pre-clinical research is to evaluate the ability of fluorescently labeled 
contrast agents for the detection and monitoring of bladder cancer. Currently, inhibitors 
of COX-2 (non-steroidal anti-inflammatory drugs, NSAIDs) are used both for the 
prevention and treatment of cancer but recently have been investigated for the detection 
of inflammation and cancer. Previously published studies indicate that fluorescently-
labeled COX-2 inhibitors, which bind to the active site of COX-2, are suitable candidates 
for targeted optical imaging because of their stable properties, high specificity for the 
target protein (i.e. COX-2), and ease of administration (39-42). Fluorocoxib A, a novel 
optical imaging agent, is a rhodamine-conjugated analog of indomethacin that 
selectively targets COX-2 expressing tissues, including solid tumors (43). This imaging 
agent has been extensively studied both in vitro and in vivo for the detection of 
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inflammation and cancer, demonstrating highly selective and specific uptake by COX-2-
expressing tissues when compared to surrounding normal tissues (44-46).  
 In this study, we evaluated the effects of RTKIs in human and canine bladder 
TCC cell lines in vitro. We have validated the effects of tested RTKIs to inhibit cell 
proliferation and activity of target RTKs in vitro. Treatment with several RTKIs increased 
COX-2 expression in both human and canine COX-2 positive bladder TCC cell lines. 
We also evaluated the ability of fluorocoxib A to detect and monitor the response to 
RTKIs-induced COX-2 expression in vivo using the K9TCC#Lilly xenograft mouse 
model. Specific and selective fluorocoxib A uptake correlated with the RTKIs-induced 
COX-2 expression in K9TCC#5Lilly xenograft tumors. These results indicate that 
fluorocoxib A can be used for monitoring the responses to targeted therapies in patients 
diagnosed with COX-2-expressing bladder cancer. 
 
MATERIALS AND METHODS 
Antibodies and reagents 
The antibodies for p-c-Kit (Tyr721, sc-18077), p-PDGFRβ (F-10, sc-365464), 
COX-2 (C-20, sc-1745), actin (C-4, sc-47778), and secondary donkey anti-goat (sc-
2020) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); antibody for 
COX-2 (aa 570-598, 160106) was purchased from Cayman Chemical (Ann Arbor, MI); 
antibody for c-Kit (961-976, PC34) was purchased from Millipore Sigma (Burlington, 
MA); and secondary anti-rabbit (cs-7074) were purchased from Cell Signaling 
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Technology (Danvers, MA). The receptor tyrosine kinase inhibitors (RTKIs) AZD 5438 
(AZD) and toceranib (Toc) were purchased from Tocris Bioscience (Minneapolis, MN); 
RTKIs erlotinib (Erl), gefitnib (Gef), imatinib (Ima), sorafenib (Sor), SP600125 (SP), 
vandetanib (Van), and UO126 (UO) were purchased from Cell Signaling Technology; 
RTKI axitinib (Ax) was purchased from Millipore Sigma (Burlington, MA); and RTKI 
AB1010 (AB) was purchased from ApexBio (Boston, MA) (Table 4.1). All other 
chemicals and reagents were purchased from Thermo Fisher Scientific (Pittsburgh, PA), 
unless otherwise specified. 
 
Cell Lines 
 Human bladder TCC cell lines J82, RT4, T24, UM-UC-3, 5637, SW780, and 
TCCSUP were purchased from American Type Culture Collection (ATCC, Manassas, 
VA). Cell lines were authenticated via short tandem repeat (STR) DNA profiling by 
Genetica DNA laboratories (Burlington, NC). J82 and TCCSUP cells were grown in 
MEM media supplemented with MEM non-essential amino acids and sodium pyruvate; 
RT4 and T24 cells were grown in McCoy’s media; UM-UC-3 cells were grown in MEM 
media; and 5637 and SW780 cells were grown in RPMI-1640 media. All culture media 
was supplemented with 10% fetal bovine serum, 100 I.U. penicillin, and 100 μg/mL 
streptomycin. Canine bladder TCC (K9TCC) cell lines, K9TCC#1Lillie, 
K9TCC#2Dakota, and K9TCC#5Lilly were established and characterized in the 
laboratory of Dr. Cekanova as described previously in detail (47). The K9TCC cell lines 
were grown in complete RPMI-1640 media supplemented with 10% fetal bovine serum, 
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100 I.U. penicillin, and 100 μg/mL streptomycin. All TCC cells were grown at 37°C and 
5% CO2. 
 
Proliferation (MTS) assay 
The tested bladder TCC cells were seeded in 96-well plates at a concentration of 
5 x 103 cells/well in complete media. After 24 h incubation, cells were treated with 5 µM 
concentration of the tested RTKIs (as shown in Figure 1) in complete media for an 
additional 48 h. DMSO was used as the control. After 48 h, cell viability was measured 
using the MTS CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega, 
Madison, WI) according to the manufacturer’s protocol. Briefly, 20 μl of the MTS reagent 
was added to each well and incubated with cells at 37°C for 1 h. Absorbance was 
measured at 490 nM using an FLx800 plate reader (Bio-Tek instruments, Winooski, 
VT). The data were shown as mean ± S.E. of four replicates of two independent 
experiments and normalized to the DMSO controls. 
 
Animals 
All animal experiments were performed in accordance with approved UTK 
IACUC protocols. Thirty 5-wks old, female athymic nude mice (Charles River, Boston, 
MA) were randomly divided into three groups (n=10/group). The COX-2 positive primary 
bladder TCC cell line, K9TCC#5Lilly, was injected subcutaneously (SC) at a density of 
1.7 × 105 cells mixed with a 1:1 ratio of PBS and Matrigel. After 2 weeks of tumor 
development, treatment with the RTKIs, AB1010 and imatinib, was initiated. Group 1, 
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served as the control group of mice that received the vehicle (DMSO+0.9% NaCl). The 
other two groups received the RTKIs treatments where Group 2 received AB1010 (3.75 
mg/kg) and Group 3 received imatinib (7.5 mg/kg). Injections were made intraperitoneal 
(i.p.) twice per week for three weeks. Tumor volume was calculated as: length × width2 
× 0.52 (mm3).  
 
Fluorocoxib A uptake by K9TCC#5Lilly xenograft tumors detected by IVIS Lumina 
optical imaging system in vivo 
Following the RTKIs treatment, fluorocoxib A (1 mg/kg) was administered SC. After 
fluorocoxib A administration, the mice were sacrificed, tissues were dissected, and 
imaged ex vivo. Specific fluorocoxib A uptake was detected 4 h after administration 
using the Xenogen IVIS Lumina optical imaging system with DsRed filters with 
excitation 500 to 550 nm, emission 575 to 650 nm, and background 460 to 490 nm. The 
obtained total flux (p/s) and average radiant efficiency ([p/s/cm²/sr] / [µW/cm²]) of 
labeled regions of interest (ROI) of dissected tumor and other tissues (heart, lung, 
kidney, liver, blood, spleen, pancreas, small intestine, muscle, and fat) were evaluated. 
Tumor-to-noise ratio (TNR) was generated using the average radiant efficiency of the 
tumor as the tumor fluorescence and blood as the background fluorescence (noise). 
The TNR for each treatment group (AB1010 and imatinib) was normalized to Group 1 
(control) and normalized TNR was plotted. TNR was calculated using the following 
equation:  
TNR = (tumor fluorescence) / (background fluorescence) 
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 Each dissected tumor was divided into three pieces, one piece of tumor was fixed in 
10% neutral buffered formalin for histology and immunohistochemistry (IHC) analysis. 
The second piece of tumor was placed into O.C.T. media for immunofluorescence (IF) 
detection of fluorocoxib A uptake by the tumors using fluorescence microscopy and the 
third piece of tumor was kept in RNAlater solution and stored at -80°C until Western 
blotting (WB) analysis was performed.  
 
Immunohistochemistry  
Dissected tissues from mice were formalin-fixed, paraffin-embedded, and sectioned 
at 7 μm. Hematoxylin and eosin (H&E) was performed following standard histological 
staining protocol. The IHC staining was performed as described previously (45). After 
de-paraffinization, the antigen retrieval using sodium citrate pH 6.0 was performed for 
20 min in antigen retriever (Electron Microscopy Sciences, Hatfield, PA). The blocking 
of endogenous peroxidase activity was performed by 3% H2O2 in 50% methanol for 5 
min, followed by the blocking of non-specific signal using protein block solution 
(BioGenex, Fremont, CA). Tissues were incubated with the COX-2 primary antibody, 
followed by the incubation with the specific biotinylated secondary antibodies, 
streptavidin/HRP detection system, and visualized by 3,3'-Diaminobenzidine (DAB) 
staining. Nuclei were counter-stained with hematoxylin and slides were cover-slipped 
and evaluated using a Leitz DMRB microscope. The images were captured by a DP73 
camera attached to microscope using CellSens Standard software (Olympus, 
Pittsburgh, PA). 
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Western blotting analysis 
The tested bladder TCC cells were seeded in 10 cm tissue culture dishes at a 
concentration of 2 x 106 cells/dish in complete media. After 24 h incubation, cells were 
treated with 5 µM concentration of the tested RTKIs (as shown in Figure 2) and with 0, 
1, 5, and 10 µM of AB1010 and imatinib (as shown in Figure 3) in complete media for an 
additional 24 h. DMSO was used as the control. The cell lysates and tissue samples 
were lysed in ice-cold RIPA buffer supplemented with protease and phosphatase 
inhibitors cocktail (1 mM PMSF; 1 μg/ml aprotinin; 1 μg/ml leupeptin; 5 mM Na3VO4; 
5 mM NaF) and briefly sonicated on ice. Protein concentrations were measured using 
Pierce® BCA protein assay (Thermo Scientific, Rockford, IL). Equal amount of proteins 
was loaded onto SDS-PAGE gels and transferred to nitrocellulose membranes. After 
blocking, the membranes were incubated with primary antibodies overnight at 4˚C, 
followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1: 
3,000 dilution) for 1 h at room temperature. The immuno-reactive bands were visualized 
using the ECL prime chemiluminescence system (GE Healthcare Life Sciences, 
Marlborough, MA) and the images were captured using the BioSpectrum® 815 imaging 
system (UVP, Upland, CA). Densitometry analysis was performed using the 
VisionWorks acquisition and analysis software (UVP). 
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Statistical analysis 
Statistical analysis was conducted using the paired Student's t-test to establish 
significant differences among treatment groups. Results were considered statistically 
significant at *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
RESULTS 
RTKIs treatment inhibited cell viability but increased COX-2 expression in tested 
bladder TCC cells 
Tested RTKIs treatment significantly inhibited cell viability in all human and 
canine bladder TCC cells as shown in Fig. 4.1. Response to RTKIs treatment correlated 
with the RTKs expression profile of the tested bladder TCC cells and the specific target 
of the RTKIs For instance, AZD5438 is a potent cyclin dependent kinase inhibitor and 
demonstrates significant anti-proliferative activity in tumor cells (48). Cell viability was 
significantly inhibited in tested bladder TCC cells after AZD treatment as compared to 
the control. Bladder TCC cells that do not have high RTKs expression, such as h-J82 
and h-UM-UC-3 cells, did not respond to RTKIs that target PDGFR and c-Kit activity as 
compared to bladder TCC cells that have high RTKs expression, such as h-T24, h-
TCCSUP, and K9TCC cells.  
Previously published studies demonstrate that treatment with RTKIs increases 
COX-2 expression in oral squamous cell carcinoma (32) and bladder TCC (29) cells in 
vitro. To investigate the effects of RTKIs treatment in the tested bladder TCC cells, the 
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cells were treated with 5 µM doses of each inhibitor for 24 h. Cell lysates were collected, 
and WB analysis was performed. As shown in Fig. 4.2, there was no increase in COX-2 
expression in the COX-2 negative bladder TCC cell lines (h-J82, h-RT4, h-T24, and h-
UM-UC-3). In the COX-2 positive bladder TCC cell lines (h-5637, h-SW780, h-TCCSUP, 
K9TCC#1Lillie, K9TCC#2Dakota, and K9TCC#5Lilly), several of the tested RTKIs 
treatment significantly increased COX-2 expression including AB1010 and imatinib. 
 
AB1010 and imatinib inhibited phosphorylation of RTKs but increased COX-2 
expression in tested bladder TCC cells in a dose-dependent manner 
 We further investigated the effects of RTKIs, AB1010 and imatinib, using the 
COX-2 positive bladder TCC cell lines, h-5637, h-TCCSUP, K9TCC#1Lillie, and 
K9TCC#5Lilly. The cells were treated with 0, 1, 5, 10 µM concentrations of AB1010 and 
imatinib for 24 h. Cell lysates were collected, and WB analysis was performed. AB1010 
and imatinib selectively targets the c-Kit and PDFGR receptors which are 
overexpressed in bladder TCC cells. As shown in Fig. 4.3A, p-c-Kit expression was 
detected in either human bladder TCC cell line and total c-Kit expression was not 
detected in h-5637 cells. Both AB1010 and imatinib decreased c-Kit expression in h-
TCCSUP cells in a dose-dependent manner. AB1010 and imatinib inhibited the 
phosphorylation of PDGFRβ in h-5637 and h-TCCSUP cells. Both AB1010 and imatinib 
increased COX-2 expression in the h-5637 cells in a dose-dependent manner. Imatinib, 
but not AB1010, increased COX-2 expression in the h-TCCSUP cells in a dose-
dependent manner.  
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As shown in Fig. 4.3B, p-c-Kit expression was detected in either K9TCC cell line 
but both AB1010 and imatinib decreased c-Kit expression in K9TCC#1Lillie cells in a 
dose-dependent manner. AB1010 increased c-Kit expression whereas imatinib 
decreased c-Kit expression in K9TCC#5Lilly cells. AB1010 increased p-PDGFRβ 
expression in both tested K9TCC cell lines in a dose-dependent manner while imatinib 
decreased the phosphorylation of PDGFRβ. Despite inhibiting cell viability and RTKs 
protein expression, both AB1010 and imatinib increased COX-2 expression in the tested 
K9TCC cell lines in a dose-dependent manner. These results are consistent with the 
response to RTKIs treatment in the h-TCC cell lines (Fig. 4.3A) and suggest the 
activation of alternative pro-survival signaling pathways. 
 
Detection of RTKI-induced COX-2 expression in K9TCC#5Lilly xenograft tumors 
by fluorocoxib A 
 Thirty 5-wks old, female athymic nude mice were randomly divided into three 
groups (n=10/group). The COX-2 positive primary TCC cell line, K9TCC#5Lilly, was 
injected subcutaneously (SC) at a density of 1.7 × 105 cells mixed with a 1:1 ratio of 
PBS and Matrigel. After 2 weeks of tumor development, treatment with the RTKIs, 
AB1010 and imatinib, was initiated. Group 1, served as the control group of mice that 
received the vehicle (DMSO+0.9% NaCl). The other two groups received the RTKIs 
treatments where Group 2 received AB1010 (3.75 mg/kg) and Group 3 received 
imatinib (7.5 mg/kg). Injections were made intraperitoneal (i.p.) twice per week for three 
weeks. Body weight (g) and tumor volume (mm3) for each mouse were recorded three 
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times per week. Average body weight per mouse (g) and relative tumor volume was 
plotted as shown in Fig. 4.4A and 4.4B. Neither the injection of K9TCC#5Lilly cells nor 
RTKIs treatment had any adverse effects on the growth of the mice over time as no 
significant differences in body weight was observed between groups. After two weeks of 
RTKIs treatment, there was an increase in relative tumor volume for Group 2 – AB1010 
and Group 3 – imatinib when compared to the control group. Values represent mean ± 
standard error of each recording. 
 After RTKIs treatment, fluorocoxib A was administered subcutaneously (1 mg/kg) 
followed by imaging of the mice. After 4 h uptake, the mice were sacrificed, and the 
dissected tissues were photographed ex vivo (Fig. 4.4C). Fluorescent imaging of the 
dissected tissues was performed using the Xenogen IVIS Lumina optical imaging 
system to detect fluorocoxib A uptake. Higher uptake and increased intensity of 
fluorocoxib A was observed in Group 2 and Group 3 when compared to Group 1 
(control) as shown in Fig. 4.4D. Obtained average radiant efficiencies 
([p/s/cm²/sr]/[µW/cm²]) of each organ were plotted (data not shown). Average radiant 
efficiency values of the tumors were normalized to blood (TNR) and fold changes in 
fluorocoxib A uptake were plotted (Fig. 4.4E). There is an increase in average radiant 
efficiency in the tumors of mice from Group 2 and Group 3 when compared to the 
control, indicating an increased uptake of fluorocoxib A. Values represent mean ± 
standard error of each TNR. 
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RTKI-induced COX-2 expression in K9TCC#5Lilly xenograft tumors detected by 
IHC and WB analysis 
 The RTKI-induced COX-2 expression in K9TCC#5Lilly xenograft tumors was 
detected by IHC (Fig. 4.5A) and WB analysis (Fig. 4.5B). Tumors from mice in Group 2 
(AB1010) had higher COX-2 expression when compared to tumors from mice in Group 
1 (control) and Group 3 (imatinib). This result was also confirmed by WB analysis of the 
dissected tumors from each group. The tumors from Group 2 and Group 3 had higher 
COX-2 expression when compared to the tumors from Group 1. Densitometry analysis 
of COX-2 protein bands from WB analysis was performed using VisionWorks acquisition 
and analysis software (UVP) (Fig. 4.5C). The specific uptake and increased intensity of 
fluorocoxib A (Fig. 4.4) in the K9TCC#5Lilly xenograft mouse model correlated with the 
RTKI-induced COX-2 expression both in vitro (Fig. 4.2 and 4.3) and in vivo (Fig. 4.5). 
 
DISCUSSION 
Bladder cancer remains one of the most expensive malignancies to treat 
primarily due to high rates of recurrence (1). In recent years, targeted therapies are 
commonly used as a treatment option for patients diagnosed with cancer because they 
are well-tolerated with few side effects, unlike standard chemotherapeutic agents. A 
common challenge associated with targeted therapies is the activation of alternative 
pro-survival signaling pathways, such as the COX-2 pathway, resulting in acquired drug 
resistance. Many of the molecular mechanisms of drug resistance remains unknown. 
Another challenge for the detection of bladder cancer, is that conventional optical 
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imaging modalities have several limitations, including poor ability to detect bladder 
cancer at the early stages and poor differentiation of tumor margins during resection 
procedures (38). These challenges drive the need for novel therapeutic options and 
better detection of bladder cancer to improve prognostic outcomes for patients.  
In this study, we evaluated the effects of RTKIs on human and canine bladder 
TCC cell lines in vitro. We have validated the effects of tested RTKIs to inhibit cell 
proliferation and the activity of RTKs, c-Kit and PDGFRβ, in vitro. Treatment with 
several RTKIs increased COX-2 expression in both human and canine COX-2 positive 
bladder TCC cell lines. Response to RTKIs treatment correlated with the RTKs 
expression profile of the tested bladder TCC cells and the specific target of the RTKIs 
as shown in Fig. 4.1. Bladder TCC cells that do not have high RTKs expression, such 
as h-J82, T24, and h-UM-UC-3 cells, did not respond to RTKIs as compared to bladder 
TCC cells that have high RTKs expression, such as h-5637, h-TCCSUP, and K9TCC 
cells. As shown in Fig. 4.2, in the COX-2 positive bladder TCC cell lines, several of the 
tested RTKIs treatment increased COX-2 expression, including AB1010 and imatinib. 
AB1010 and imatinib selectively target the c-Kit and PDFGRα/β receptors which are 
overexpressed in bladder TCC cells (17-19). Despite inhibiting the phosphorylation of 
the c-Kit and PDGFRβ receptors, AB1010 and imatinib increased COX-2 expression in 
a dose-dependent manner in the tested COX-2 positive bladder TCC cell lines (Fig. 
4.3). 
When induced, COX-2 plays a key role in promoting angiogenesis, cell 
proliferation, and inhibiting apoptosis (33-36). COX-2 is overexpressed in many types of 
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cancer, including bladder cancer, and is often an indicator of poor patient prognosis 
(37). Previously published studies indicate treatment with chemotherapeutic agents and 
targeted therapies increased COX-2 expression in bladder cancer cells, glioma cancer 
stem cells (CSCs), non-small cell lung cancer cells, and oral squamous cell carcinoma 
cells in vitro (29-32, 49). These results suggest that COX-2 expression can be affected 
by the intrinsic tumor microenvironment and the response to therapies. The results from 
our study are consistent with previous findings that following treatment with RTKIs, 
COX-2 expression is upregulated by several RTKIs, including AB1010 and imatinib. 
Based on these results, we proposed that despite inhibiting cell viability and the activity 
of RTKs, the COX-2 signaling pathway is activated which leads to acquired drug 
resistance. Therefore, the molecular mechanism of action for the RTKIs-induced COX-2 
expression needs to be elucidated. 
 To further investigate the RTKIs-induced COX-2 expression, we evaluated the 
ability of fluorocoxib A to detect and monitor the effects of RTKIs treatment in vivo using 
the K9TCC#5Lilly xenograft mouse model. Neither the injection of K9TCC#5Lilly cells 
nor RTKIs treatment had any adverse effects on the growth of the mice over time as no 
significant differences in body weight was observed between groups (Fig. 4.4A). After 
two weeks of RTKIs treatment, there was an increase in relative tumor volume for 
Group 2 – AB1010 and Group 3 – imatinib when compared to the control group (Fig. 
4.4B). The increase in relative tumor volume in Groups 2 and 3 indicates a negative 
response to RTKIs treatment and suggests acquired drug resistance. Following RTKIs 
treatment, fluorocoxib A was administered and ex vivo imaging was performed. Higher 
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uptake and increased intensity of fluorocoxib A was observed in the K9TCC#5Lilly 
xenograft tumors from Group 2 (AB1010) and Group 3 (imatinib) when compared to 
Group 1 (control) as shown in Fig. 4.4D. The RTKI-induced COX-2 expression in 
K9TCC#5Lilly xenograft tumors was confirmed by IHC (Fig. 5.5A) and WB analysis (Fig. 
5.5B). The xenograft tumors from mice in Group 2 (AB1010) had higher COX-2 
expression when compared to tumors from mice in Group 1 (control) and Group 3 
(imatinib). The specific uptake and increased intensity of fluorocoxib A (Fig. 4.4) by the 
K9TCC#5Lilly xenograft tumors correlated with the RTKI-induced COX-2 expression 
both in vitro (Fig. 4.2 and 4.3) and in vivo (Fig. 5.5).  
The challenges associated with the detection of bladder cancer also contribute to 
the high bladder cancer recurrence rates, driving the need for improved diagnostic 
imaging techniques. To improve diagnostic imaging tools during cystoscopy procedures, 
a key focus in pre-clinical research is to evaluate the ability of fluorescently labeled 
contrast agents for the detection and monitoring of bladder cancer (38, 50-52). 
Previously published studies indicate that fluorescently-labeled COX-2 inhibitors (i.e. 
fluorocoxib A) are suitable candidates for targeted optical imaging because high 
specificity for the target protein (i.e. COX-2) (39-42). Fluorocoxib A has been 
extensively studied both in vitro and in vivo for the detection of inflammation and cancer, 
demonstrating highly selective and specific uptake by COX-2-expressing tissues when 
compared to surrounding normal tissues (44-46, 53). Our results are consistent with 
previously published studies that fluorocoxib A specifically detects COX-2 expression 
bladder cancer cells in vivo. In this study, we also validated the ability of fluorocoxib A to 
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detect molecular changes in COX-2 expression after treatment with the targeted 
therapies, AB1010 and imatinib. These results indicate that fluorocoxib A is sensitive 
and specific enough to detect the early responses to therapy in COX-2 expressing 
bladder cancer. A limitation of fluorescent probes is that they typically target a specific 
biomarker expressed within the tumor (i.e. site of inflammation or tumor). Fluorocoxib A 
specifically targets COX-2 expressing cells and tissues which suggests that if there is 
no COX-2 expression present, there will be no uptake of the fluorocoxib A.  
We previously published a study which concludes that co-treatment of AB1010 
with indomethacin, an NSAID, abrogates the AB1010-induced COX-2 expression in 
TCC cells in vitro (29). Future in vivo studies need to be conducted to evaluate the 
ability of fluorocoxib A to monitor the effects of RTKIs and NSAIDs co-treatment using 
the COX-2 positive TCC xenograft mouse model. In conclusion, the results of this study 
indicate that optical imaging agent, fluorocoxib A, can be used for monitoring the early 
responses to targeted therapies in patients diagnosed with COX-2-expressing bladder 
cancer. Early detection and monitoring of treatment responses can provide better 
prognostic outcomes for patients diagnosed with bladder cancer. 
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APPENDIX 
 
Table 4.1 Receptor tyrosine kinase inhibitors (RTKIs) treatments. 
Receptor Tyrosine Kinase Inhibitors (RTKIs) Treatments 
Drug Abbreviation Dose Target 
1. Control DMSO -  -  
2. Axitinib Ax 5µM c-kit, PDGFR 
3. AB1010 AB 5µM c-Kit, PDGFR 
4. Toceranib Toc 5µM c-Kit, PDGFR 
5. Imatinib Ima 5µM c-Kit, PDGFR 
6. Erlotinib Erl 5µM EGFR 
7. Gefitinib Gef 5µM EGFR 
8. Sorafenib Sor 5µM 
B-Raf, c-Kit, 
VEGFR 
9. Vandetanib Van 5µM 
B-Raf, c-Kit, 
VEGFR 
10. AZD5438 AZD 5µM CDKI 
11. SP600125 SP 5µM cJUN 
12. UO126 UO 5µM MEK 
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Figure 4.1 RTKIs treatment inhibited cell viability in tested bladder TCC cells. 
(A) Human bladder transitional cell carcinoma (TCC) cell lines, J82, RT4, T24, UM-UC-
3, 5637, SW780, TCCSUP; and (B) canine bladder TCC cell lines, K9TCC#1Lillie, 
K9TCC#5Lilly, and K9TCC#2Dakota were treated with 5 µM concentration of tested 
receptor tyrosine kinase inhibitors (RTKIs) for 48 h. Cell viability was measured by MTS 
assay and compared to the control (DMSO) groups. Values represent mean ± standard 
error of four replicates from two independent experiments; paired Student's t test, 
*p < 0.05 and **p < 0.01. 
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Figure 4.1  
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Figure 4.2 RTKIs treatment increased COX-2 expression in tested bladder TCC 
cells as detected by WB analysis. 
(A) Human bladder TCC cell lines, J82, RT4, T24, UM-UC-3, 5637, SW780, TCCSUP; 
and (B) canine bladder TCC cell lines K9TCC#1Lillie, K9TCC#5Lilly, and 
K9TCC#2Dakota were treated with 5 µM concentration of tested RTKIs for 24 h. The 
expression of COX-2 was determined by WB analysis and actin was used as a loading 
control. Several of the tested RTKIs increased COX-2 expression in the COX-2 positive 
bladder TCC cell lines, including AB1010 and imatinib. No increase in COX-2 
expression was detected in the COX-2 negative bladder TCC cell lines. Densitometry 
evaluation of COX-2/actin protein bands from WB analysis was performed using 
VisionWorks acquisition and analysis software (UVP). Values represent 
mean ± standard error from two independent experiments; paired Student's t test, 
*p < 0.05. 
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Figure 4.2  
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Figure 4.2 (continued) 
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Figure 4.3 AB1010 and imatinib inhibited the phosphorylation of RTKs but 
increased COX-2 expression in tested bladder TCC cells in a dose-dependent 
manner. 
(A) Human bladder TCC cell lines, 5637, and TCCSUP; and (B) canine bladder TCC 
cell lines, K9TCC#1Lillie and K9TCC#5Lilly were treated with 0, 1, 5, and 10 µM of 
AB1010 and imatinib for 24 h in serum free media. The expression of p-c-Kit, c-Kit, p-
PDGFRβ, and COX-2 proteins were determined by WB analysis. Actin was used as a 
loading control. No p-c-Kit expression was detected in the tested bladder TCC cells. 
Both AB1010 and imatinib inhibited the phosphorylation of PDGFRβ in the h-TCC cell 
lines in a dose-dependent manner. AB1010 increased the phosphorylation of PDGFRβ 
in both K9TCC#1Lillie and K9TCC#5Lilly while AB1010 inhibited the phosphorylation of 
PDGFRβ in the tested K9TCC cell lines. Despite inhibited phosphorylation of RTKs, 
both AB1010 and imatinib increased COX-2 expression in a dose-dependent manner in 
the tested human and canine bladder TCC cell lines.  
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Figure 4.3 
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Figure 4.4 Detection of RTKI-induced COX-2 expression in K9TCC#5Lilly 
xenograft tumors by fluorocoxib A. 
(A, B) Average body weight and relative tumor volume for each group were plotted as 
shown. After 2wks of treatment, mice were injected with fluorocoxib A (1mg/kg, s.c.) and 
imaged using the IVIS Lumina system. (C, D) After sacrificing the mice, the dissected 
organs were photographed and imaged ex vivo. Organs from left to right: Row 1 - tumor, 
heart, lung; Row 2 - kidney, liver, blood; Row 3 - pancreas & spleen, small intestine, 
muscle, and fat. Blue circle depicts the region of interest (ROI) area used for IVIS image 
data analysis. (E) Relative average radiant efficiency values of fluorocoxib A uptake by 
the K9TCC#5Lilly xenograft tumors were plotted as tumor-to-noise ratio (TNR). TNR 
values were calculated as described in the methods section. Higher uptake and 
increased intensity of fluorocoxib A was detected in Group 2 (AB1010) and Group 3 
(imatinib) when compared to Group 1 (control).  
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Figure 4.4 
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Figure 4.5 RTKI-induced COX-2 expression in K9TCC#5Lilly xenograft tumors 
detected by IHC and WB analysis. 
The upregulation of COX-2 by AB1010 and imatinib in the K9TCC#5Lilly xenograft 
tumors was detected by (A) IHC and (B) WB analysis. K9TCC#5Lilly xenografts in mice 
from Group 2 (n=8, AB1010) and Group 3 (n=10, imatinib) treatment had higher COX-2 
expression when compared to mice from Group 1 (n=9, control). The higher COX-2 
expression in Group 2 and 3 correlates to increased fluorocoxib A uptake. Brown color 
is positive staining for tested COX-2 protein expression. Representative images were 
taken by Olympus Microscope, objective 10x, scale bar 100µm. Actin was used as a 
WB loading control. (C) Densitometry evaluation of COX-2/actin protein bands from WB 
analysis was performed using the VisionWorks acquisition and analysis software (UVP). 
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Figure 4.5  
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CHAPTER V DISCUSSION 
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GENERAL DISCUSSION 
 
The studies presented in this dissertation were designed to: 1) evaluate the 
effects of several receptor tyrosine kinase inhibitors (RTKIs) and/or COX inhibitors (non-
steroidal anti-inflammatory drugs, NSAIDs) both in vitro and in vivo using human and 
canine bladder transitional cell carcinoma (TCC) cell lines, 2) evaluate the novel optical 
imaging agent, fluorocoxib A, for the detection of bladder cancer in vivo using the 
established carcinogen-induced bladder cancer mouse model, and 3) evaluate the 
ability of fluorocoxib A to monitor the responses to targeted therapies for the treatment 
of bladder cancer in vivo using the xenograft mouse model. 
 
SUMMARY OF RESULTS 
 
Inhibition of RTKIs-induced COX-2 expression in bladder TCC cells in vitro 
The basal expression profile of RTKs, COXs, and their downstream targeted 
proteins were tested in human and canine bladder TCC cells by WB analysis as shown 
in Fig. 2.1. The K9TCC cell lines had relatively higher expression of the RTKs, PDGFRα 
and c-Kit, as compared to levels detected in the h-TCC cell lines. Human UM-UC-3 and 
T24 cells had very low detectable COX-2 expression, whereas h-5673, K9TCC#1Lillie, 
and K9TCC#5Lilly cells had high COX-2 expression. All tested bladder TCC cell lines 
had high expression levels of Akt1/2/3, COX-1, ERK1/2, and the COX-2 transcription 
factor, NF-κB.  
This study demonstrates the effectiveness of the RTKIs, axitinib and AB1010, to 
significantly inhibit cell viability and induce apoptosis of human and canine bladder TCC 
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cell lines in vitro in a dose-dependent manner. To evaluate the effects of the tested 
RTKIs on cell viability, an MTS assay was performed. Both axitinib and AB1010 
significantly inhibited cell viability in a dose-dependent manner in both human and 
canine bladder TCC cells, despite the varying expression of the RTKs (c-Kit and 
PDGFR) in the different bladder TCC cell lines. Axitinib may also be effective in 
inhibiting additional signaling pathways, other than the ones tested in this study and 
further evaluation is required to determine the direct mechanism of action for axitinib in 
those cell lines with low RTKs expression. AB1010 compared to axitinib was more 
effective in inhibiting cell viability at a 10µM dose in both the human and canine cell 
lines (Fig. 2.2). The bladder TCC cell lines with high c-Kit and PDGFR expression (h-
UM-UC-3, K9TCC#1Lillie, and K9TCC#5Lilly) were more sensitive to axitinib and 
AB1010 treatment after 48 h when compared to the cell lines that do not have high 
RTKs expression.  
We evaluated the effects of the RTKIs on apoptosis by performing Annexin V 
staining to determine the percentage of apoptotic cells. Axitinib and AB1010 significantly 
induced apoptosis in both human and canine bladder TCC cells after 24 h treatment 
(Fig. 2.3). This result was confirmed by evaluating the caspase 3/7 activity and 
downstream cleavage of PARP (cPARP) in the h-5637 and K9TCC#1Lillie bladder TCC 
cells (Fig. 2.4). A significant increase in caspase 3/7 activity and cPARP was observed 
in the h-5637 and K9TCC#1Lillie bladder TCC cells after axitinib treatment in a dose-
dependent manner. AB1010 significantly increased caspase 3/7 activity at a 10µM dose 
in the K9TCC#1Lillie cells.  
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The inhibition of cell viability and induced apoptosis in bladder TCC cells by 
AB1010 treatment positively correlated with the expression levels of PDGFRα and c-Kit 
receptors in tested cells. AB1010 inhibited phosphorylation of the c-Kit receptor in a 
dose-dependent manner causing the inhibition of cell viability and activation of caspase 
3/7 in K9TCC#1Lillie cells (Fig. 2.5). Despite AB1010 significantly inhibiting cell viability 
and phosphorylation of c-Kit, increased levels of COX-2 and NF-κB expression were 
detected in both h-5637 and K9TCC#1Lillie bladder TCC cells (Fig. 2.6A). The increase 
in COX-2 and NF-κB expression suggests drug resistance to the AB1010 therapy. This 
is also supported by the reduced effectiveness of axitinib and AB1010 to induce 
apoptosis and increased p-Akt expression after treatment in the K9TCC#1Lillie cells 
(Fig. 2.3 and 2.6). These results are consistent with previous studies that indicate after 
treatment with chemotherapy and targeted therapies (i.e. AB1010) there is an 
upregulation of COX-2 expression in glioma cancer stem cells, non-small cell lung 
cancer, and oral squamous cell carcinoma (1-4). 
To further investigate the AB1010-induced COX-2 expression in the h-5637 and 
K9TCC#1Lillie cells, co-treatment of AB1010 (AB) and indomethacin (indo) was 
performed. MTS results demonstrate that co-treatment of AB + Indo is more effective at 
inhibiting cell viability than either treatment alone (Fig. 2.7A). We evaluated the effects 
of the AB + Indo co-treatment on the AB1010-induced COX-2 expression by performing 
WB analysis. These results show that the AB1010-induced COX-2 expression in both h-
5637 and K9TCC#1Lillie bladder TCC cells can be inhibited by co-treatment of AB + 
Indo (Fig. 2.7 B & C).  To confirm the inhibition of COX-2 activity, we measured the 
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levels of prostaglandins E2 synthase (PGE2) released into the cell culture media after 
AB + Indo co-treatment. PGE2 levels were significantly decreased by the AB + Indo co-
treatment in both h-5637 and K9TCC#1Lillie cells (Fig. 2.8). Our results are consistent 
with previous studies that indicate the COX-2/PGE2 signaling pathway exerts pro-
oncogenic effects through activation of RTKs in colorectal cancer and non-small cell 
lung cancer (5, 6). By inhibiting the activity of the COX-2 signaling pathway, the cancer 
cells are more sensitive to the RTKIs therapy, resulting in a more effective treatment 
option for bladder cancer.  
Our results indicate that co-treatment of RTKIs and NSAIDs can abrogate the 
RTKIs-induced COX-2 expression in bladder TCC cells and result in a more effective 
treatment than either therapy alone (Fig. 5.1). These results are consistent with 
previous studies that demonstrate the effectiveness of NSAIDs in combination with 
other therapies (i.e. chemotherapy and RTKIs) for the treatment of cancer and support 
our findings that co-treatment of RTKIs and NSAIDs might indicate better clinical 
success for the treatment of bladder cancer (5-11).  
Bladder cancer has an extremely high recurrence rate due to many contributing 
factors, including the lack of novel therapies for the treatment of bladder cancer over the 
past several decades. However, as previously mentioned, drug resistance is a common 
challenge associated with targeted therapies (i.e. RTKIs) due to several reasons, 
including the activation of alternative signaling pathways (i.e. COX-2 signaling pathway), 
activation of a bypass oncoprotein, and the presence of secondary mutations in the 
RTKs which ultimately results in tumor progression. This drives the need for the 
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characterization of the molecular mechanisms of resistance and early detection of the 
responses to targeted therapies to improve patient prognostic outcomes. Further 
studies need to be conducted to evaluate the molecular mechanisms of resistance for 
the RTKI-induced COX-2 expression in bladder TCC cells following treatment with 
AB1010.  
 
Detection of early and late stage bladder cancer by fluorocoxib A in vivo 
Fluorocoxib A is a novel optical imaging agent that selectively targets Cox-2, 
which commonly is overexpressed in several types of cancers, including bladder 
cancer. In this study, we confirmed that fluorocoxib A could detect both the early and 
late stages of Cox-2-expressing bladder cancer using the carcinogen-induced bladder 
cancer mouse model.  
Over the course of 12- and 18- weeks, immunocompetent mice were exposed to 
the carcinogen, N-butyl-N-4-hydroxybutyl nitrosamine (BBN), in drinking water (Fig. 
3.1A). Following BBN exposure, fluorocoxib A was administered subcutaneously 
followed by ex vivo imaging of the BBN-induced bladder tumors in mice using the IVIS 
Lumina imaging system. As shown by the representative white light images, the 
bladders from BBN-exposed mice were larger when compared to the control mice (Fig. 
3.2A). Significantly higher uptake and increased intensity of fluorocoxib A was observed 
in the bladders from mice exposed to BBN when compared to the control mice (Fig. 
3.2C, D, & E). These results demonstrate the specificity of fluorocoxib A uptake by the 
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cancerous bladder tissue when compared to normal urothelium, where no fluorocoxib A 
uptake was recorded.  
The BBN-induced bladder cancer progression from normal urothelium, to 
inflammation and hyperplasia, and to invasive carcinoma in mice was confirmed by H&E 
staining (Fig. 3.3 - left). The progression of bladder carcinogenesis was also confirmed 
by the presence of increased expression of Ki67 expressing cells in bladder carcinomas 
from mice exposed to BBN (Fig. 3.3 - middle). In addition, uroplakin 1a (UP1a), a 
protein that is highly expressed in normal bladder urothelium, was downregulated in 
BBN-induced bladder cancer (Fig. 3.3 - right). These results are consistent with 
previous studies using the BBN carcinogen for the development of bladder cancer in 
rodents (12-14). In addition to the development of bladder cancer, fluorocoxib A uptake 
correlated with presence of neoplastic lesions in the bladders of mice exposed to BBN 
when compared to mice from the control group.  
To confirm the ability of fluorocoxib A to detect Cox-2-expressing bladder cancer, 
the upregulation of Cox-2 in BBN-induced bladder cancer was confirmed by 
immunohistochemistry (IHC) (Fig. 3.4A) and western blot (WB) analysis (Fig. 3.4B). 
Bladder carcinomas in mice from Group 3 had significantly higher Cox-2 expression 
when compared to normal urothelium in mice from Group 1 and bladder inflammation 
and hyperplasia in mice from Group 2. The specific uptake and increased intensity of 
fluorocoxib A (Fig. 3.2) in carcinogen-induced bladder cancer of mice exposed to BBN 
correlated with the progression of bladder carcinogenesis (Fig. 3.3) and with the 
increased Cox-2 expression (Fig. 3.4). The detection of fluorocoxib A uptake by the 
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tumors and upregulation of Cox-2 in BBN-induced bladder cancer can also be detected 
by immunofluorescence (IF) staining in fresh tissue samples that have been preserved 
in O.C.T. media. The results from the IF evaluation would further confirm the correlation 
between increased fluorocoxib A uptake and Cox-2 expression in the tumors.  
The results from this study demonstrate the range of fluorocoxib A uptake 
between the groups and indicates the ability of fluorocoxib A to detect different stages of 
Cox-2-expressing bladder inflammation and tumors, including the early and late stages 
of bladder cancer. These results are consistent with pre-clinical studies that 
demonstrated the effectiveness of fluorocoxib A to be highly specific and selective for 
detecting Cox-2-expressing inflammation and cancers, including bladder and non-
melanoma skin cancer (15-18).  
Collectively, these results demonstrate the strong potential for fluorocoxib A to be 
used as a diagnostic tool for the detection of early and late stage bladder cancer in vivo. 
As previously mentioned, a limitation to targeted optical imaging agents is the necessity 
for the molecular target (i.e. Cox-2) to be expressed in the cancerous cells. If there is no 
Cox-2 expression in the bladder tumors, no fluorescence uptake will be detected and 
further histopathology will be required to confirm the presence of neoplastic lesions. 
This is a common challenge with precision medicine as there is no one method or 
technique that can encompass all cases, but the development of novel optical imaging 
agents such as fluorocoxib A can significantly improve diagnostic and resection 
procedures for bladder cancer patients to reduce the risk of recurrence. Further studies 
can be conducted to evaluate the improved efficacy of fluorocoxib A for the detection of 
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bladder cancer compared to current detection imaging techniques including white light 
and fluorescent cystoscopy procedures.  
 
Detection of RTKIs-induced COX-2 expression in bladder TCC cells by 
fluorocoxib A in vivo 
Previously published studies from our lab have demonstrated that treatment with 
the RTKI, AB1010, increases COX-2 expression in oral squamous cell carcinoma (4) 
and TCC (19) cells in vitro. To further investigate these results, we evaluated the effects 
of several RTKIs on COX-2 expression in human and canine bladder TCC cells by WB 
analysis. Consistent with previous results from our studies, despite inhibiting the 
phosphorylation of the c-Kit and PDGFRβ receptors, AB1010 and imatinib increased 
COX-2 expression in the tested COX-2 positive human and canine bladder TCC cell 
lines in vitro (Fig. 4.2 & 4.3).  
Prior to evaluating fluorocoxib A in vivo, we evaluated the specificity of 
fluorocoxib A to detect COX-2-expressing bladder TCC cells in vitro. We confirmed the 
specific uptake over time of fluorocoxib A is correlated to COX-2 expression in bladder 
TCC cells in vitro (Fig. 5.2A&B). The detection of fluorocoxib A also correlated with 
COX-2 expression in bladder TCC cells in vitro (Fig. 5.3). Based on the results from this 
study and our previous studies, we proposed that fluorocoxib A can detect and monitor 
the RTKIs-induced COX-2 expression in bladder cancer cells using the K9TCC#5Lilly 
xenograft mouse model in vivo.  
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Immunosuppressed mice were randomly divided into three groups and the COX-
2 positive bladder TCC cell line, K9TCC#5Lilly, was injected subcutaneously into the 
shoulder of the mice. After tumor development, treatment with the RTKIs AB1010 and 
imatinib was initiated. There was an observed increase in relative tumor volume for both 
treatment groups when compared to the control group (Fig. 4.4B). Following RTKIs 
treatment, fluorocoxib A was administered subcutaneously, followed by ex vivo imaging 
of the xenograft tumors using the IVIS Lumina imaging system. Significantly higher 
uptake and increased intensity of fluorocoxib A was observed in the K9TCC#5Lilly 
xenograft tumors from mice with AB1010 and imatinib treatments when compared to the 
control mice (Fig. 4D & E).  
The RTKI-induced COX-2 expression in K9TCC#5Lilly xenograft tumors was 
confirmed by IHC (Fig. 4.5A) and WB analysis (Fig. 4.5B). The xenograft tumors from 
mice in Group 2 (AB1010) had higher COX-2 expression when compared to tumors 
from mice in Group 1 (control) and Group 3 (imatinib). The specific uptake and 
increased intensity of fluorocoxib A (Fig. 4.4) by the K9TCC#5Lilly xenograft tumors 
correlated with the RTKI-induced COX-2 expression both in vitro (Fig. 4.2 and 4.3) and 
in vivo (Fig. 4.5) 
These results indicate that fluorocoxib A is sensitive and specific enough to 
detect early responses to targeted therapies in COX-2 expressing bladder cancer. The 
results from this study are valuable in the fact that the responses to targeted therapies 
can be monitored over time to determine if a patient is responding to therapy or if drug 
resistance is occurring. The ability to monitor the responses to therapy using a targeted 
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imaging agent, such as fluorocoxib A, can significantly improve patient outcomes over 
time.  
 
FUTURE DIRECTIONS 
 
The results of our studies have demonstrated that: 1) Co-treatment of RTKIs and 
NSAIDs proves to be a more effective treatment strategy than either therapy alone in 
COX-2 positive human and canine bladder TCC cells in vitro, 2) Fluorocoxib A has the 
ability to detect both the early and late stages of COX-2-expressing bladder cancer in 
vivo, and 3) Fluorocoxib A is sensitive and specific enough to detect the early 
responses to targeted therapies in COX-2-expressing bladder cancer in vivo.  
Previously published studies have indicated that there is cross-talk between the 
RTKs and COX-2 signaling pathways which promotes the progression of cancer and 
can result in intrinsic or acquired drug resistance (2, 20-25). These studies also 
demonstrated that simultaneous inhibition of both signaling pathways results in a more 
effective treatment response than targeting the RTKs or COX-2 signaling pathway 
alone. The mechanisms of action for the RTKI-induced COX-2 upregulation is currently 
unknown and needs to be further elucidated. To determine the mechanisms for the 
RTKIs-induced COX-2 expression, the role of the RTKs (c-Kit, EGFR, PDGFR, VEGFR, 
etc.) signaling pathway can be evaluated in vitro. The cross-talk between the RTKs and 
COX-2 signaling pathways in bladder cancer can be evaluated via knockdown of the 
RTKs by siRNA in human and canine TCC cells, followed by RTKIs treatment in vitro. 
The results of these experiments would further test the idea that there is a direct 
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connection between the signaling pathways if the RTKI-induced COX-2 expression is 
not observed when the RTKs expression is knocked down. Evaluation of the RTKs 
downstream signaling targets, such as the PI3K/Akt and MAPK pathways, would be 
necessary to determine which downstream signaling proteins have a connection to the 
COX-2 signaling pathway. These results would suggest that when the RTKs signaling 
pathway is inhibited by RTKIs treatment, the COX-2 signaling pathway is activated as a 
pro-survival pathway to promote tumor progression and drug resistance to the RTKIs. In 
addition, these results would further support the findings that co-treatment of RTKIs and 
NSAIDs is necessary for better therapeutic responses for bladder cancer than either 
treatment alone due to cross-talk between the signaling pathways.  
To further investigate the efficacy of the co-treatment of RTKIs (ex. AB1010 and 
imatinib) with COX inhibitors (ex. indomethacin) for the treatment of bladder cancer 
needs to be validated in vivo. A xenograft mouse model of bladder cancer would be 
necessary to test the efficacy of the individual treatments alone and in combination. At 
the end of the treatment regimen, fluorocoxib A can be administered prior to euthanasia 
to allow for in vivo imaging of the responses to therapy. The administration of 
fluorocoxib A would allow for the visualization of COX-2 expression in the xenograft 
tumors after treatment to confirm the conclusion that co-treatment of RTKIs with 
NSAIDs abrogates the RTKI-induced COX-2 expression in TCC cells. The results of 
these studies would also confirm the ability of fluorocoxib A to detect and monitor 
molecular changes within the tumor in response to targeted therapies. Following 
success of the xenograft mouse model, these results can be applied to other COX-2-
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expressing cancers, such as colorectal cancer and oral squamous cell carcinoma, to 
determine if this treatment strategy can be applied to different types of cancer in vitro 
and in vivo.  
To date, many RTKIs are FDA-approved for treatment of human cancers 
including breast, colorectal, lung, and renal cell carcinoma (26-32). To overcome both 
intrinsic and acquired resistance to standard chemotherapy and targeted therapies, 
combination treatment strategies have proven to be more effective than a single 
therapeutic agent. The results of our studies are consistent with this notion and 
demonstrate the effectiveness of co-treatment with RTKIs and NSAIDs. This therapeutic 
strategy can be applied to other COX-2 positive cancers that overexpress RTKs, such 
as lung and colorectal cancer, where FDA-approval has already been granted to treat 
patients with RTKIs. Both RTKIs and NSAIDs have been extensively evaluated and are 
well-tolerated compared to standard chemotherapy and radiation. Pending results from 
in vitro and in vivo pre-clinical studies, the effectiveness of co-treatment with RTKIs and 
NSAIDs in humans, can be evaluated by performing clinical trials with patients who 
qualify for RTKIs therapy and are diagnosed with COX-2 expressing cancers. These 
studies have the potential to provide a more effective treatment strategy for patients 
diagnosed with cancers that have high RTKs and COX-2 expression for a better 
prognostic outcome and reduce the likelihood of developing drug resistance. 
CONCLUSION 
 
These studies indicate that in human and canine COX-2-positive bladder cancer, 
several receptor tyrosine inhibitors (RTKIs) upregulate COX-2 expression after 
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treatment despite inhibiting cell viability, inducing apoptosis, and inhibiting the 
phosphorylation and downstream signaling of the RTKs, indicating acquired drug 
resistance. Co-treatment of RTKIs and COX inhibitors increases the efficacy of RTKIs 
targeted therapy in vitro. Furthermore, the optical imaging agent, fluorocoxib A, is 
specific and sensitive enough to detect molecular changes in COX-2 expression to have 
the ability to monitor the responses to targeted therapies in vivo. In conclusion, these 
results can be used to study novel targeted therapeutic strategies for the treatment of 
bladder cancer and as a model for monitoring the responses to targeted therapies in 
patients diagnosed with COX-2 positive bladder cancer to improve prognostic 
outcomes. 
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APPENDIX 
Figure 5.1 Representation of RTKIs-induced COX-2 expression in bladder cancer 
cells. 
(A) Receptor tyrosine kinase inhibitors (RTKIs) inhibit the activity of their target 
receptors and downstream signaling targets (PI3K/Akt, JNK, MAPK) to inhibit cell 
proliferation and induce apoptosis. (B) RTKIs treatment also shows increased COX-2 
expression and subsequent PGE2 levels in the cells, indicating drug resistance. The 
mechanism of action for this is still unknown. (C) Co-treatment of RTKIs with COX-
inhibitors abrogates the RTKI-induced COX-2 expression resulting in a more effective 
treatment option than either treatment alone.  
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Figure 5.2 Fluorocoxib A uptake correlates with COX-2 expression in human and 
canine bladder TCC cells in vitro.  
(A) Human and canine bladder TCC cells were treated with 5 µM fluorocoxib A at 
various time points (0.5, 1, 6, 12, 24, and 48 h). Fluorescence was measured to 
determine fluorocoxib A uptake by bladder TCC cells. Fluorescence readings were 
normalized to the corresponding cell viability values which were obtained by performing 
an MTS assay after fluorocoxib A treatment. (B) Cells were grown in the absence (-) or 
presence (+) of fetal bovine serum (FBS) for 24 h. The expression of COX-2 was 
evaluated by WB analysis. Actin was used as a loading control. The specific uptake of 
fluorocoxib A by bladder TCC cells correlated with the basal expression of COX-2 in the 
bladder TCC cells in vitro.  
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Figure 5.3 Fluorocoxib A detection correlates with COX-2 expression in human 
and canine bladder TCC cells in vitro. 
(A) Specific uptake of fluorocoxib A (1 µM; 1 h R.T.) by human and canine bladder TCC 
cells in vitro (red color). (B) Basal COX-2 expression of bladder TCC cells was detected 
by Alexa Fluor488nm dye (green color) (C) Cells were counterstained with DAPI for 
nuclei detection (blue color). (D) Co-localization of fluorocoxib A and COX-2 was 
confirmed by merging the individual images (yellow color).  
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